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Abstract 
In healthy subjects Deep Inspiration (DI) transiently dilates the airways, while many 
asthmatics show bronchoconstriction by a mechanism which is incompletely 
understood. I investigated how the method of assessment affects the response. The 
response as measured by specific airway conductance (SGaw) appeared to contradict 
that measured by forced expiration. This led to the formulation of a novel hypothesis 
to explain the asthmatic bronchoconstrictor response: That the negative intra-thoracic 
pressure associated with DI may temporarily increase airway oedema and thus reduce 
lumenal diameter. This was tested by comparing the effects of non-forced with forced 
inspiration (through resistance). In the asthmatic group, forced inspiration produced 
significantly more bronchoconstriction. 
Airway hyperresponsiveness in asthma has been attributed to impaired ability of DI to 
stretch airway smooth muscle. The seminal study `confirming' this, I argue, is flawed. 
I have re-tested the hypothesis. The asthmatic response was significantly greater than 
the control response even when DI was prohibited. Asthmatic hyperresponsiveness is 
therefore not attributable entirely to an abnormal asthmatic response to DI. 
Many asthmatics display an apparent capacity for unlimited airway narrowing in 
response to bronchial challenge; most healthy subjects demonstrate a maximal 
(limited) response. The maximal response measured by a DI independent index 
represented a greater % change from baseline than the maximal established by a DI 
dependent index. This suggested some bronchoprotection resulting from DI but also 
the existence of a distinct mechanism which ultimately limited narrowing. 
I reasoned that the capacity for unlimited airway narrowing is most likely a function 
of smaller airways. I investigated indices of small airway function and found they 
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predicted the ultimate response much earlier in challenge than FEV 1, suggesting a 
possible practical test of the capacity for unlimited narrowing. 
I postulate that the clearly established but limited relationship between the responses 
to DI and bronchial challenge may reflect the dependence of the response to DI on the 
degree of inflammation within the airway wall whereas the response to challenge may 
be determined by its overall thickness. 
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1.1 The response to Deep Inspiration 
In 1961 Nadel and Tierney (1) observed, in the context of pre-induced 
bronchoconstriction in healthy subjects, a bronchodilator response to deep inspiration 
(DI). In 1968 Froeb and Mead (2) studying healthy subjects, found an increase in 
anatomical dead space, suggesting dilatation of the airways, following DI. Subsequent 
studies have used a number of methods to assess the response to DI. The most 
commonly used method is to compare expiratory flow during a forced expiration 
following a partial (P) inspiration with the expiratory flow at the same lung volume 
during a forced expiration following maximum (M) inspiration, the M/P ratio (3-11). 
Using this method, in 1978, Fish et al (12) reported the response to DI in asthmatic 
and control subjects. They demonstrated a reduction in forced expiratory flow post DI 
with no significant effect being observed in the control group. This finding of a 
difference between asthmatic and healthy subjects suggested that the phenomenon 
might have an important clinical relevance. In 1981 Fish et al (13) again, compared the 
response to DI (in the context of induced bronchoconstriction) between asthmatics 
and healthy controls, this time by comparing changes in airway resistance. They 
showed that the reduction in airway resistance after DI seen in healthy subjects was 
diminished or absent in asthmatics. These differences fuelled interest. Numerous 
studies have since reported the response to DI in healthy subjects (2,3,14), 
asthmatics (4-6,11,15,16) and both asthmatics and healthy controls (7-10,17-21) 
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which have demonstrated that the functional response to deep inspiration is different 
between the two groups. 
It is the difference in the asthmatic and healthy response to DI that has generated 
much of the interest in this phenomenon. It suggests that an understanding of the 
mechanism underlying the response to DI might reveal something fundamental about 
the pathophysiology of asthma. Studies in healthy subjects have generally shown a 
bronchodilating response to DI (7-10,14,18,22). The bronchodilatation post DI in 
healthy subjects is largely attributable to a reduction in airway smooth muscle tone. 
This explanation is consistent with the enhanced bronchodilating effect of DI seen in 
the context of methacholine induced bronchoconstriction in both asthmatic (4-6,21) 
and healthy subjects (1,8,21) and with diminution of the bronchodilating effect of DI 
following administration of ß2 sympathetic agonists (6,16,23). 
In asthma the reported response has been variable (4-6,11,15,16). While milder 
asthmatics simply display a more limited bronchodilator response, subjects with more 
severe asthma show bronchoconstriction post DI. Indeed some studies have identified 
an inverse relationship between the bronchodilating effect of DI and severity (5,16, 
17,20). The mechanism underlying the abnormal asthmatic response is not fully 
established. A diminution of the bronchodilating effect of DI can be explained by a 
reduction in the degree of stretch imposed on smooth muscle by DI in asthmatic 
subjects because of the relative unlinking of the airway from the retractile force of the 
surrounding parenchyma due to the increased adventitial thickness of the airway wall 
(24). An additional mechanism however is required to explain the bronchoconstrictor 
response observed in some asthmatics. 
The time course to restitution of baseline after the effects of DI may shed some light 
on the underlying mechanisms responsible for the different responses to DI observed. 
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Green and Mead (25) measuring forced expiratory flow at various time intervals after 
deep inspiration in healthy subjects found most of the bronchodilating effect of DI 
had worn off after only 5 seconds. Lim et al (5) looked at this issue in two groups: 
asthmatics (who demonstrated bronchoconstriction after DI) and a group in which 
equally severe obstruction was induced by a bronchoconstrictor (who demonstrated 
bronchodilatation after DI). The time course for restitution of baseline airway calibre 
differed between the two groups. The group that demonstrated a bronchoconstrictive 
response to DI returned to baseline with a time constant of 30 seconds, in the 
bronchodilator group the time constant was 10 seconds. This difference has been 
reproduced in subsequent studies (26,27). The difference seems to suggest a 
fundamentally different mechanism may be responsible for the changes post DI in the 
two groups. The time course to restitution of baseline has implications not only in 
studies of the effects of a deep inspiration but also in the practical application of lung 
function testing clinically. In a study by Malmberg et al (28) healthy subjects 
performed two stepwise methacholine tests, with either 6 or 3 min between dose 
steps. The percentage decrease in FEV 1 per mg of inhaled methacholine decreased 
from 2.6 (1.9-5.2) to 1.7 (0.8-2.3) (median, interquartile-range) when the time interval 
was shortened. The results suggest that the deep inhalation associated with the FEV 1 
manoeuvre decreases the bronchial tone in airways constricted by methacholine for 
more than 3 minutes. In the same paper (28) a separate study was reported in which 
the response to methacholine was measured in healthy subjects who performed an 
FEV 1 manoeuvre (and the preceding deep inhalation) before inhalation of 
methacholine. When an FEV 1 manoeuvre was performed immediately before 
methacholine, the first FEV 1 measured 3 min after provocation was higher (77% of 
basal FEV 1) than if a pre-methacholine FEV 1 manoeuvre was not performed (64% of 
10 
basal FEV1). This effect of a pre-methacholine FEV1 manoeuvre was also 
demonstrated at 2,4 and 6, but not at 10 min after the start of methacholine 
inhalation. If an FEV 1 manoeuvre was not performed before methacholine, the 
second and subsequent FEV1 measured in constricted airways was higher than the 
first, and of similar magnitude to the first FEV1 in tests where a pre-challenge FEV1 
manoeuvre was performed. Implying the `protective' effect of DI occurred whether it 
was performed either before or after administration of methacholine. 
Thus far the discussion has focussed on a putative mechanism within the airways 
causing an alteration in their function after DI, (after the pre DI lung volume has been 
restored) - `hysteresis of the airway'. One popular hypothesis considers the possibility 
of the same or a similar mechanism having a direct effect on the lung parenchyma - 
`parenchymal hysteresis'. Given the close interdependent relationship between the 
airways and parenchyma the two mechanisms could not function entirely 
independently. Hysteresis within the parenchyma could result in lower lung recoil 
pressure post DI and a diminished retractile force on the airway wall, leading to a 
narrowing of the airways post DI. The net effect on the airways would therefore be a 
balance between airway and parenchymal hysteresis- the `relative hysteresis 
hypothesis' (4,7,14,23,29). The origin of this putative `parenchymal hysteresis' is 
unclear, it may result from the inherent hysteresis of surfactant, it may be due to a 
differences in the number of alveoli contributing to volume during inspiration and 
expiration, or it may be related to the behaviour of the respiratory bronchioles 
including the contractile Kapanci cells (4). In support of this hypothesis, appropriate 
changes in hysteresis of the quasi-static transpulmonary pressure-volume (Ptp-V) 
curve of the lungs (taken as an index of parenchymal hysteresis) have been 
demonstrated following induced bronchoconstriction (7) or bronchodilatation (23) but 
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the numbers studied were very small and the relevance to spontaneous asthma is 
unclear. There are also several theoretical reservations about the use of the area 
within a (Ptp-V) curve as a relevant index of parenchymal hysteresis: 
1. The constraints of in vivo testing mean that the pressures are measured in quasi- 
static conditions, not actually static. I. e. flow exists. The force involved in 
overcoming the flow resistance will cause inspiratory pressures to be more negative 
and expiratory pressures to be more positive, thus causing an over-estimation of static 
pressure volume hysteresis. In those with more severe airflow obstruction (more 
severe asthmatics with lower M/P ratios) the over-estimation will be greater. 
Depending on flow rates, measurements on anaesthetised dogs (30) show this over- 
estimation to be up to 5x that seen in true static Ptp-V curves. In other words changes 
in the airway alone could account for some of the apparent increases in'parenchymal 
hysteresis' seen accompanying low M/P ratios. 
2. The hysteresis demonstrated in Ptp-V curves relates to the difference in recoil 
pressure at isovolumic points on the inspiratory and expiratory phases between TLC 
and RV. In the assessment of an M/P ratio the relevant difference in recoil pressure is 
that between isovolumic points on the expiratory limb of a full curve (i. e. when 
expiration has been preceded by a full inspiration) and the recoil pressure during an 
expiration begun at around end tidal inspiration. The expiratory limb of the tidal curve 
probably most closely represents such a pressure. Such differences are very small in 
comparison to the inspiratory and expiratory phases of the full cycle. The full curve 
hysteresis has been used as a surrogate for the hysteresis we are interested in. There is 
no evidence that it is a good surrogate. 
3. Even if we accept the principle of 'parenchymal hysteresis' and its effect on the 
airway, there is no reason why this should be relatively greater in asthmatic compared 
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with normal subjects. Evidence that it actually is greater is sparse. This evidence 
relates to changes in the Ptp-V curve in response to bronchoconstrictors and 
bronchodilators, as outlined above (4,7,8,23). Explanations employed in these 
papers suggest a more peripheral distribution of receptors in asthmatic subjects. This 
may or may not be the case but there is no evidence to back it. Even if true, it does not 
explain why M/P ratios are less than 1 in many asthmatic subjects. It also does not 
explain why the M/P ratio rises as asthma improves. This phenomenon is observed 
both longitudinally (16) and in cross section (5). 
Although the relative hysteresis hypothesis only relies on an abnormal balance 
between airway and parenchymal hysteresis the assumption of an increased 
parenchymal hysteresis is often implicit in a number of the papers that invoke it. The 
marked hyperinflation seen in asthma is in part due to the loss of lung recoil pressure, 
`reduced tone' (31,32). Where there is reduced tone in a system there is often reduced 
hysteresis. 
Furthermore, the relative hysteresis hypothesis does not explain all empirical findings, 
for example, the finding in spontaneous asthma of an increase in M/P ratio following 
a bronchodilator (16). Also, after methacholine challenge, M/P can increase markedly, 
suggesting dominant airway hysteresis. This would imply wider airways during 
deflation but no corresponding DI-induced change in anatomical dead space was seen 
(4). This finding was attributed to a possible difference in the generations of airways 
contributing to M/P ratio and those contributing to the measurement of anatomical 
dead space. This may or may not be the case but the finding in the same study, in 
asthmatic subjects, of an increase in isovolumic forced expiratory flow post DI (M/P 
> 1) in conjunction with a reduction in SGaw is more difficult to explain and certainly 
cannot be accounted for by the relative hysteresis hypothesis. 
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If this finding were to be reproduced any new alternative hypothesis would clearly 
have to account for it. Before the development of any novel hypothesis to explain the 
bronchoconstricting response to DI in asthmatic subjects can be considered, we first 
need to take into account the variability in reported responses both in asthma and 
healthy subjects. 
The majority of studies in healthy subjects report a bronchodilating response to DI (7- 
10,14,18), indeed it is this `typical' response that various hypotheses have attempted 
to explain. However, a number of studies have reported either no response or even 
bronchoconstriction in response to DI (1-3,17,19,20). In asthmatic subjects the 
reported response to DI has been even more variable, with results varying from 
bronchoconstriction (15,18,19) to bronchodilatation (7-10) with most studies 
reporting a variable response within this subject group (4-6,11,16,17,20). Clearly a 
large part of the observed variability in asthmatic subjects can be explained by the 
variability in severity of asthma, with some studies identifying an inverse relationship 
between the bronchodilating effect of DI and severity (5,16,17,20). One further 
source of apparent variability in response, which has not been formally explored, is 
variability in the method used to assess that response. The most commonly used 
method uses forced expiratory flow in the M/P ratio (3-11). Even within this method 
there remains considerable room for variability. The lung volume, as a percentage of 
vital capacity (% VC), at which the flow rates are compared has not been 
standardised, volumes used have ranged from 25% to 50%VC. Other methods to 
assess the response to DI include a comparison of airway resistance (Raw) or specific 
airway conductance (SGaw) before and after a deep breath. (1,4,5,14-16,18-21), 
and the volume of the dead space before and after DI (2). Some authors have reported 
the response to DI as assessed by two different indices in the same group of subjects. 
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Lim et al (5) found that the changes in SGaw were consistent with the changes in max 
flow (M/P ratio) in two groups of asthmatics, one demonstrating bronchoconstriction, 
the other bronchodilatation post DI. Pellegrino et al (21) found, in the context of 
induced bronchoconstriction, that in asthmatic individuals, DI had a significantly 
smaller effect on flow but not on Raw compared with normal individuals. And Burns 
et al (4) found disagreement between these two indices in a group of asthmatics, with 
M/P >1 but a reduced SGaw post DI. This disagreement may simply be an anomaly 
but we note that many studies in asthmatics using M/P report an apparent 
bronchodilator response to DI (M/P >1)(6-1 1) whilst those studies using SGaw in 
asthmatics suggest DI has a bronchoconstricting effect. (5,15,16,18,19). 
In chapter 4 we assess the dependence of the apparent response to DI on the method 
used to assess it. The findings appear to shed some light on the underlying 
mechanisms and an alternative hypothesis is suggested. This hypothesis is then tested 
in the study reported in chapter 8. 
1.2 The Ultimate Response to Methacholine Challenge -a maximal (plateau) 
response or unlimited narrowing. 
The most commonly used index of bronchial responsiveness is PD20(FEVI). A single 
index however, cannot reflect all facets of the response to incremental bronchial 
challenge. The presence of a maximal (plateau) response or the converse, the capacity 
for unlimited airway narrowing shown by many asthmatics is a less familiar facet of 
the response to bronchial challenge than PD20(FEVI) but potentially far more 
important. The obvious clinical correlate would appear to be the susceptibility to 
severe, potentially fatal, exacerbations of asthma. 
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In 1984 Woolcock et at (33) described the shape of the dose response curve to 
bronchial challenge in asthmatic and healthy subjects. Bronchial challenge (with 
histamine) was continued until either a 60% fall in FEV 1 or a maximal `plateau' 
response occurred. The dose response curves demonstrated a close fit to a sigmoidal 
equation and values for alpha (the position constant) and beta (the slope constant) 
could be determined. PD20(FEV1). The most commonly used index of bronchial 
responsiveness, is a hybrid index in that it is determined by both the position and the 
slope of the curve. Its usefulness lies in its robustness and repeatability. However a 
single index cannot reflect all facets of response. Perhaps the most important finding 
in the Woolcock study was that the normal and 2 mildly asthmatic subjects 
demonstrated a plateau response. I. e. in these subjects a point was reached beyond 
which no further airway narrowing occurred despite increased doses of histamine. The 
other subjects demonstrated at least a 60% fall in FEV1 in response to challenge (at 
which point the challenge was terminated) apparently demonstrating the capacity for 
unlimited narrowing. It could be argued that the presence or absence of this capacity 
for apparent unlimited narrowing is a more important facet of response than 
PD20(FEV1). It would appear to have significant implications in acute severe asthma 
and the potential for fatality. The phenomenon described by Woolcock (33) is now 
well established with most healthy subjects and some mild asthmatics demonstrating a 
plateau response (34). The proportion of subjects demonstrating the phenomenon has 
varied between studies. Much of this variability will be due to subject selection but of 
course the value to which FEV1 is allowed to fall before the presence or absence of a 
plateau response is determined will have a significant bearing on it. Intuitively it 
seems likely that the maximal fall in FEV 1 at plateau will vary, with some being 
below the 40% or even 60% threshold. Those who do not plateau prior to the given 
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`safety' threshold in a particular study probably fall into two categories: Those in 
whom a plateau would be established at a lower value of FEV1 and those who have 
the capacity for true unlimited narrowing. In an absolute sense therefore it could be 
argued that any study may be mis-positioning the dividing line in this dichotomy, 
however in a practical sense those who do plateau below such threshold (particularly 
60%) are probably more appropriately categorised as being susceptible to fatal 
exacerbations of asthma. 
Some work has been done to try and understand the `protective mechanism' that 
healthy and some asthmatic subjects seem to possess which limits airway narrowing. 
Sterk et al (35) assessed the effects of propranolol hexamethonium and indomethacin 
on the maximal response plateau. No difference from placebo was noted. They 
concluded that limitation to airway narrowing to methacholine in non-asthmatics is 
not due to a change in adrenergic, cholinergic, or ganglion-transmitted-nonadrenergic 
inhibitory activity nor to the release of prostaglandins. De Jongste et al (36) compared 
maximal bronchoconstriction in vivo and airway smooth muscle responses in vitro 
found no significant correlation. Suggesting that maximal bronchoconstriction in vivo 
is not limited by the maximal contractility of airway smooth muscle. This was 
consistent with the findings of Sterk et al (37) who found the response to combined 
histamine and methacholine was not significantly larger than the maximal response to 
histamine alone. They argued that this suggests that the plateau is due to factors other 
than limited smooth muscle activation. 
Ding et al (38) used inspiratory pulmonary resistance (RL) during tidal breathing as 
the index of airway narrowing during challenge. In subjects who demonstrated a 
plateau response there was no correlation between the concentration of methacholine 
required to double RL and the maximum value of RL. 
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Boulet et at (39) reported in a group of non-asthmatics with seasonal allergic rhinitis 
(who demonstrated an increase in airway responsiveness in the pollen season) no 
correlation between the change in PC20(FEV1) and the change in maximal response to 
challenge (A FEV 1, max) in the pollen season. 
Clearly therefore, the factors that determine the response to lower and higher dose 
MCh may be different. Aerts et al (40) used complex mathematical modelling 
(Cumulative Gaussian Distribution function and the Hofstee equation) to extrapolate 
the `early' part of FEV 1 dose response curve to estimate the plateau value. Although 
the data entered into the models was from the entire curve except the final 4 data 
points (which define the maximal response), these complex models were still rather 
inaccurate in their estimation of the plateau actually achieved. This would seem to 
suggest that the early changes in FEV1 did not actually contain the information 
required to estimate ultimate outcome i. e. the factors that determine the early changes 
in FEV1 may be different to those which determine plateau. 
Ding et al (38) also investigated the effect of lung volume on maximal airway 
narrowing in healthy subjects. Inspiratory pulmonary resistance (RL) was measured at 
functional residual capacity (FRC) and FRC -0.5 liter or FRC +0.5 liter. The 
maximum response to methacholine was markedly altered by changing lung volume. 
The maximum fall of RL was greater at FRC - 0.5 liter; and less at FRC + 0.5 liter. 
The authors conclude that changes in lung volume act to alter the forces of 
interdependence between airways and parenchyma that oppose airway smooth muscle 
contraction. One might argue further that it seems likely that the site at which this 
airway-parenchymal interdependence is most important in terms of maintaining 
airway opening is where the airways are otherwise not supported by cartilage. By the 
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same argument it could be inferred that it is here, in the small airways, where the 
maximum response to challenge may be determined. 
Brusasco et al (7) examined the relationship between quasi-static pulmonary 
hysteresis and maximal airway narrowing in healthy and asthmatic subjects. The 
quasi-static transpulmonary pressure-volume (Ptp-V) area was similar in the two 
groups at baseline. At MCh end point it was increased significantly in the group 
demonstrating an apparent capacity for unlimited narrowing yet remained unchanged 
in the group demonstrating a plateau in response. The hysteresis observed in the 
separation of the inspiratory and expiratory limbs of the Ptp-V curve is largely due to 
the closure of small airways towards the end of expiration which then, due to surface 
forces, require a greater force to re-open. I would argue therefore that the increased 
Ptp-V area seen in the first group could be accounted for entirely by an increase in the 
propensity for small airways to close completely as the lung empties. It seems likely 
therefore that subjects who display this increased propensity for complete (small 
airway) closure are more likely to display a capacity for unlimited airway narrowing 
i. e. will not display a plateau response to MCh. 
Moore et al (41) described the shape and position of the complete dose-response 
curve for inhaled methacholine in 73 normal subjects. Amongst a number of findings 
it was noted that in those who achieved a plateau in terms of the maximal flow (Vm) 
for a given lung volume (% baseline VC), the maximal fall was greater at the lower 
lung volume (30% versus 50% of VC), suggesting the greater proportionate change 
had occurred in airways of smaller caliber. It would seem therefore that the presence 
or absence of the capacity for `unlimited' narrowing is more likely to be determined 
by these airways. An in vitro study by Mitchell et al (42) reported changes in response 
to acetylcholine (ACh) with concurrent measurement of smooth muscle shortening, 
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lumenal narrowing and flow in large and small porcine bronchi. Maximum muscle 
shortening and lumen narrowing was greater in small than large bronchi. Small 
airways were 250-times more sensitive to ACh than large airways, for all 
measurements. But perhaps most interestingly high doses of ACh stopped flow in 
small bronchi, but produced a plateau in large bronchi. The cartilaginous support of 
the large airways may have protected them from unlimited narrowing, even in the 
context of maximal smooth muscle stimulation. 
The protective effect of cartilage preventing complete airway closure was more 
formally explored in an animal study (43) in which pulmonary resistance was 
significantly increased by intravenous treatment with papain in a concentration that 
produced generalized cartilage softening. Papain pretreatment also resulted in a 
substantial alteration in the pulmonary resistance-dose relationship to intravenously 
administered acetylcholine. 
The conclusions from these studies would seem to be that: (1) The ultimate outcome 
to challenge: a plateau in response or apparent unlimited narrowing is not evident 
from the responses in the early stages of challenge - at least using the standard indices 
such as FEV1. (2) There is some evidence to suggest that the capacity or otherwise for 
unlimited narrowing is determined by the small airways. 
1.3 The Relationship Between the Response to Deep Inspiration and the Response to 
Bronchial Challenge 
The relationship of the response to DI and the response to challenge can be considered 
in either direction. It is well established that the bronchodilating effects of a DI are 
augmented in the context of induced bronchoconstriction (1,4-6,8) when the airway 
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narrowing is induced by smooth muscle constriction. Interestingly in the context of 
the late response to an allergen challenge, when the principal mechanism underlying 
airway narrowing is thought to be airway inflammation, the response to DI becomes 
more bronchoconstricting compared with pre challenge responses (44). Thus the 
response to challenge does influence the response to DI. The reverse relationship has 
also been investigated. 
Fish et at in 1978 (12) reported the difference in response to DI between asthmatic 
and control subjects. Asthmatic subjects demonstrated a reduction in forced 
expiratory flow post DI with no significant effect being observed in the control group. 
In 1981 Fish et al (13) again compared the response to DI between asthmatics and 
healthy controls this time in the context of induced bronchoconstriction, on this 
occasion by comparing changes in airway resistance. The reduction of airway 
resistance following DI in controls was less or absent in asthmatic subjects. The 
results were attributed to a failure, in asthmatic subjects, of DI to stretch (and relax) 
airway smooth muscle. This led the authors to hypothesise that hyperresponsiveness 
in asthma may be caused by impaired ability of inspiration to stretch airway smooth 
muscle. Skloot et al (9) reasoned that if this hypothesis were true, then the sensitivity 
to inhaled methacholine of normal and asthmatic subjects should be the same if the 
challenge was carried out under conditions where deep inspiration was prohibited. It 
is noteworthy that studies (45) (46) (47) using specific airway conductance (SGaw) as 
the index of airway function have consistently shown hyperresponsiveness in 
asthmatic subjects. In principle such measurements are independent of DI but it is not 
clear from these papers to what extent, if any, DI was prohibited prior to the 
measurement of SGaw. The influence of any preceding DI therefore could not be 
excluded. 
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Skloot (9) performed methacholine challenge in asthmatic and control subjects under 
conditions where the prohibition of deep inspiration was formally documented. They 
found no apparent difference in the responses of the two groups. The concluded that: 
`hyperresponsiveness in asthma is caused by an impairment in the ability of 
inspiration to stretch airway smooth muscle'. This was reported widely in the medical 
literature at the time and was even noted by the lay media. 
However I have a number of reservations about this study and its conclusions: 
(1) As discussed above, a diminution of the bronchodilating effect of DI can be 
explained by a reduction in the degree of stretch imposed on smooth muscle by DI in 
asthmatic subjects (perhaps due to an unlinking of airway and parenchyma (24)). This 
could not however account for the bronchoconstrictor response seen in some 
asthmatics, for which an additional mechanism is required. 
(2) Whatever the mechanism, the diminution (or reversal) of the bronchodilating 
effect of DI on induced bronchoconstriction in asthmatics implies that if DI is 
prohibited the difference in responsiveness between asthmatic and normal subjects is 
inevitably reduced. It is therefore important to determine whether, in the absence of 
DI, there is complete loss of asthmatic hyperresponsiveness or only the relative 
diminution that would have been predicted by studies published prior to 1995 (and 
indeed since (48)). Only complete loss would support the revised (and more limited) 
hypothesis that: hyperresponsiveness in asthma can be accounted for entirely by the 
altered response to DI. 
(3) Further, there are serious theoretical reservations that the index of 
bronchoconstriction (`T') used in the Skloot study might obscure differences between 
the responses of the two groups. The `T' index is derived from `partial' forced 
expiratory manoeuvres. Since the end inspiratory lung volume (EILV) at which such 
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expiratory manoeuvres is initiated varies, , r, an index in the time domain was used. ti 
equals the forced expiratory time between 25% and 75% of the partial expiration 
divided by the natural log of 3. Skloot et al showed that the response to methacholine 
as measured by ti was similar in asthmatic and control subjects and concluded that 
asthmatic hyperresponsiveness was attributable to a lack of smooth muscle relaxation 
with deep inspiration. The volume independence of the index relies on the assumption 
that the volume-time relation during forced expiration approximates to a 
monoexponential function. Under this assumption Skloot et al argue that the ti index is 
`equal to the reciprocal of the mean slope of the flow volume curve between 25% and 
75% of the forced expiration'. In fact, although not stated by Skloot, the assumption 
implies that the descending limb of the flow volume curve is rectilinear and that r is 
equal to the reciprocal of the gradient of the entire slope of the flow volume curve. 
Whilst this is a reasonable assumption in healthy young subjects, with airway 
narrowing the flow volume curve is characteristically concave and therefore the 
volume time curve is not mono-exponential. The more severe the airway narrowing, 
the further the deviation from this assumed curve. This implies that ti is not 
independent of volume, rather it will decrease if tidal breathing occurs over a higher 
volume range. For a given degree of bronchoconstriction therefore, an increase in 
EILV (or RV) will result in a lower value of ti suggesting less bronchoconstriction. 
The rise in EILV as bronchoconstriction progresses therefore would tend to mask the 
change in r. If the rise in EILV was greater in asthmatic subjects than in healthy 
subjects, the masking effect would be greater in that group. The net effect would 
therefore be to underestimate the difference in responsiveness between the two 
groups. 
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The discussions in the papers by Fish et al (13) and Skloot et al (9) focus on asthmatic 
bronchial hyperresponsiveness as a generic entity. As we discussed above no single 
index of response is likely to be able to reflect all aspects of response. The 
relationship of the response to deep inspiration and the perhaps more important facet 
of responsiveness, the ultimate outcome to challenge (maximal, plateau response or 
unlimited narrowing) seems to have received less attention in the literature. In non- 
asthmatic subjects, particularly in the context of induced bronchoconstriction, deep 
inspiration induces airway dilation. The degree of `bronchoprotection' afforded by 
this mechanism and whether, it alone could account for the limitation to airway 
narrowing seen in some subjects has been addressed by some authors. 
Sterk et al (49) measured the responses to challenge in non-asthmatic subjects using 
`partial' flow (Vp) - from a forced expiration not preceded by a deep inspiration, as 
well as the `maximum' flow (Vm) - from a forced expiration preceded by a deep 
inspiration, derived at 40% of control vital capacity. A maximal response plateau was 
demonstrated in all subjects based on Vp. The plateau for Vp occurred after a greater 
percentage fall than in the case of Vm. Similar findings were reported by Moore et al 
(41). Both indices Vp and Vm were determined at 30% and 50% of VC. At each lung 
volume in those who achieved a plateau the mean maximal decrease was greater in 
Vp than Vm. Maximal fall at the plateau was greater at lower lung volumes (30% 
versus 50% of VC). The difference in the level of the plateau for Vp and Vm merely 
reflects previously reported data on the increased bronchodilating effect of deep 
inspiration in the context of induced bronchoconstriction. 
Pellegrino (10) reported a novel and rather complex approach to the same question. 
The effect of DI was quantified as the linear regression coefficient of the percent 
decrements of maximal (Vm) versus partial (Vp) forced expiratory flow at 50% of 
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FVC over the initial steps of challenge (= `MP slope'). Airway sensitivity was 
inferred from the MCh provoking dose (PD) causing Vm50 or Vp50 ('maximal' and 
`partial' flows at 50% VC) to decrease by 40% or FEV1 by 15% (PD15 FEV1). The 
absence of a limit to bronchoconstriction was predicted by either MP slope or any PD 
with accuracies between 71 and 81%, but with an accuracy of 87% by a combined 
function including MP slope and PD40Vp50. The complexity of the model, I believe, 
probably hides some simple and previously established relationships. Although not 
absolute, the correlation between PD20(FEV1) and the presence or absence of a 
plateau is reported. The prediction of the ultimate outcome of challenge given 
information about a response beyond the initial stages of challenge is perhaps no 
surprise, although PD15(FEV1) will of course occur earlier in challenge than 
PD20(FEV1) the principle I believe is the same. Also, although the MP slope appears 
to be telling us about the response to DI the index does of course contain information 
about the response of the small airways over the initial steps of challenge. It may be 
this component of the index that contains the predictive power. Nevertheless, It is 
clear that DI does offer some degree of bronchoprotection in the context of induced 
bronchoconstriction. Indeed it my well be that a large bronchodilating response to DI 
could cause a plateau to occur above rather than below whatever safety threshold is 
set (say 40% or 60% decline in FEV1) thus re-classifying the subject as one with 
limited as opposed to apparent unlimited narrowing. The response to DI is therefore 
clearly an important factor at least in terms of limiting the maximal plateau response. 
However the existence of a plateau in a partial flow response to challenge implies that 
some `mechanism' limiting airway narrowing in response to challenge would appear 
to be operating independently of the effects of deep inspiration. 
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1.4 Other Factors Which May Influence the Response to Bronchial Challenge= 
Abnormal Smooth Muscle Function and The Thickness of the Airway Wall 
1.4.1 Abnormal Smooth Muscle Function 
The functional hallmark of asthma is the variability of its airway obstruction. By 
definition the severity of the airway obstruction will vary over short periods of time 
either spontaneously or in response to stimuli. Such stimuli may be either 
bronchodilating e. g. P2 agonists or bronchoconstricting e. g. methacholine. The 
magnitude of response in terms of the bronchodilatation is often used as a diagnostic 
tool clinically. The magnitude of response, measured as the dose of methacholine 
required to achieve a 20% fall from a baseline in the value of FEV1, is essential to the 
definition of bronchial hyperresponsiveness. It is nevertheless the swiftness of the 
response that also characterizes asthma clinically. 
It would seem almost intuitively obvious that in comparison to non asthmatic subjects 
a swift and exaggerated bronchodilating response to a drug known to relax bronchial 
smooth muscle and a similarly swift and exaggerated bronchoconstricting response to 
a substance known to constrict bronchial smooth muscle would seem to imply that the 
abnormality in asthma lies in the behavior of the smooth muscle. It is perhaps 
surprising therefore that the correlation between in vivo responsiveness and in vitro 
reactivity of smooth muscle whenever examined has been found to be very weak. De 
Jongste et al (36) compared maximal bronchoconstriction in vivo and airway smooth 
muscle responses in vitro and found no significant correlation. Vincenc et al (50) 
compared in vivo responses to histamine in 14 patients prior to thoracotomy with in 
vitro responses to histamine of both parenchymal and bronchial tissue. Although a 
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wide range of responsiveness occurred in vivo, as measured by the histamine 
inhalation test, the variation in the in vitro dose-response curves was negligible. There 
was no correlation between the dose of histamine that resulted in a 20% reduction in 
forced expiratory volume in one second and the concentration of histamine producing 
50% of the maximal response in vitro. The authors concluded that the findings raised 
the possibility that airway hyperresponsiveness may not result from an intrinsic 
abnormality of airway smooth muscle. The following year Armour et al (51) 
measured the airway responsiveness of a group of 25 patients scheduled for lung 
resection. 10 of 25 patients had a greater than or equal to 20% fall in FEV1 in 
response to inhaled methacholine (responders), with PD20 FEV 1 values ranging from 
0.6 to 7.3 µmo1. The sensitivity to carbachol and histamine of the bronchial smooth 
muscle resected from these patients was similar in tissue from responders and non- 
responders. There was no correlation between in vivo responsiveness to methacholine 
and in vitro sensitivity to carbachol or histamine. The volume of smooth muscle in 
some of these airway preparations was quantitated. There was a significant correlation 
between the maximum tension change in response to histamine and the volume of 
smooth muscle in each airway. There was no similar correlation for carbachol. Again 
the authors concluded that in vivo responsiveness could not be explained in terms of 
smooth muscle sensitivity. Cerrina et al (52) measured human bronchial muscle 
responses to histamine and isoproteronol in vitro, similar conclusions were reached. 
Nagai (53) reported results from 41 patients who had been enrolled in a larger 
(mortality) study who died, came to autopsy, and provided adequate tissue to 
quantitate lesions. All subjects had moderate to severe chronic airflow obstruction and 
a broad range of responses to 250 micrograms isoproterenol inhalation. Thus although 
not exclusively asthmatic some subjects had clear positive responses to the inhaled 
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drug. The relationships between pulmonary lesions and both bronchodilator response 
and variability of FEV 1 were investigated. Airway responsiveness to isoproterenol in 
vivo was positively correlated with bronchial eosinophilia, bronchial inflammation, 
and bronchiolar fibrosis ('re-modeling'). However airway smooth muscle was not 
related to airway responsiveness or variability. 
Despite these negative findings latterly there has been some renewed interest in 
smooth muscle function in relation to asthmatic hyperresponsiveness (27). This seems 
to have been born out of the noted abnormal response to deep inspiration. Much of 
this work has focused on the importance for normal functioning of periodic stretch 
and relaxation of airway smooth muscle inherent in the normal breathing cycle (54). It 
has been argued that the reduced mechanical load on airway smooth muscle in 
asthma, due to the unlinking of airway and parenchyma (55,56) may itself have a 
secondary effect on smooth muscle function (57). Given the known effects of stretch 
on reducing smooth muscle tone (28,58), and the cyclical stretch of smooth muscle 
inherent in tidal breathing, it seems plausible to argue that if the unlinking of the 
airway and parenchyma (due to adventitial thickening in asthma) were to lead to a 
reduced degree of stretch during every inspiration of a tidal breath then that may itself 
lead to an abnormal development of tone, with smooth muscle in a more `latched' 
state i. e. a `semi-permanent' state of contraction. The functional importance of this 
possible `semi-permanent' state as opposed to the simple loss or diminution in asthma 
of the transient relaxation in tone following a deep inspiration discussed above is not 
clear. Whether real or not and whether functionally important or not, these argued 
changes in smooth muscle behavior are not primary but secondary to geometrical 
changes in the airway wall. Moore et al (59) found the prohibition of DI during 
methacholine challenge in healthy subjects led to a greater decline in FEV 1 (measured 
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at the end point of challenge and itself necessitating a preceding DI). The authors 
argued that failure of periodic inflation may interfere with the bronchodilating effect 
of DI, and this may be fundamental to the difference in bronchodilatation caused by 
DI in asthmatics and normal subjects. The implication that the abnormality resides in 
the behavior of the smooth muscle however would appear to be founded on a 
significant number of assumptions. 
In a computational model (60) based on an earlier model by Wiggs et al. (61) the 
effects of the morphologically determined increased airway smooth muscle mass, 
adventitial mass, and submucosal mass observed in patients with asthma and chronic 
obstructive pulmonary disease (COPD) on the increase in airway resistance in 
response to a bronchoconstricting stimulus were investigated. Although increased 
adventitial thickness was found to increase constriction by reducing airway and 
parenchymal interdependence and increased submucosal thickness also led to greater 
lumenal occlusion for any degree of smooth muscle shortening, the authors concluded 
that the increased muscle mass was likely to be the most important abnormality 
responsible for the increased resistance observed in response to bronchoconstricting 
stimuli. Two assumptions however were implicit in this model: (i) The increased 
muscle thickness in asthma led to a proportionate increase in maximal muscle tension. 
Whilst an increase in muscle thickness would seem likely to be associated with some 
increase in maximal muscle tension, it is worth remembering that this re-modeling is 
`pathological' and evidence that the increase in tension would be proportionate to the 
increase in thickness is lacking. (ii) That airway wall thickness remains constant 
during bronchoconstriction. In fact a later study by Mitchell et al (62) using isolated 
bronchi from pigs demonstrated that in fact it increases. This increase in wall 
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thickness would of course narrow the airway lumen -a significant contributory factor 
to increased resistance during bronchoconstriction not taken account of in the model. 
In summary therefore evidence that abnormal smooth muscle function is responsible 
for the abnormal behavior of asthmatic airways in general and hyperresponsiveness in 
particular is far from conclusive. As hinted at by some of the modeling above the 
effect of geometric changes such as the thickened airway wall, particularly in the 
context of induced bronchoconstriction needs further exploration. 
1.4.2 Thickness of the airway wall 
Let us consider another mathematical model. This model is considered for illustrative 
purposes only. 
Using a basic mathematical model published by Moreno et al (63) a later study (64) 
used morphometric data from postmortem specimens of lung obtained from both 
asthmatics and non-asthmatics. The internal and external perimeter of the airways and 
the submucosal and mucosal thicknesses were measured in small and large, asthmatic 
and non-asthmatic airways. The increased wall area in asthma was found to be due to 
increased areas of epithelium, muscle, and submucosa. These data were fed into the 
Moreno model, which calculated the change in airway resistance in a typical 
asthmatic and healthy airway for a given degree of smooth muscle shortening. The 
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From this model the modest differences in airway wall thickness had little effect on 
airways resistance at base line. However very large increases of airways resistance are 
observed in the asthmatic airway at degrees of smooth muscle shortening that would 
produce only small increases in resistance in the normal airway. Let us now consider 
the converse, bronchodilatation in response to ß2 agonists in asthma. From the graph 
we see that if such treatment relaxed smooth muscle to reduce the degree of 
contraction from say 30% to 15% shortening for example, then the reduction in 
resistance in the asthmatic airway is large and probably symptomatically detectable, 
whereas the corresponding change in resistance in the normal airway is barely 
perceptible. I reproduce these data and this model here not as proof of the overriding 
importance of airway wall thickness in determining airway resistance but merely to 
illustrate that variations in wall thickness could theoretically account for many of the 
observed features in asthma. 
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We need to review the empirical evidence for a relationship between airway wall 
thickness and changes in resistance in order to assess its relative contribution. Several 
papers have reported on this (24,65-70). 
Tiddens et al (68) studied lung tissue specimens from 72 patients with different 
degrees of COPD who were operated on for a solitary peripheral lung lesion. 
Maximum expiratory flow and the reversibility of airflow obstruction determined 
preoperatively were significantly related to the airway wall area but not to the smooth 
muscle area. 
Okazawa et al (67) studied freshly excised dog lung lobes and concluded that the 
magnitude and variability of airway smooth muscle shortening and airway narrowing 
in response to maximal constricting stimuli are influenced by mechanical factors 
related to airway wall geometry. 
A post mortem study (66) found the adventitial, submucosal, and muscle area of the 
asthmatic airways were greater than those of COPD and control subjects. These 
parameters were also greater in the 8 patients with fatal asthma compared with the 7 
patients with non-fatal asthma. 
In another mathematical model using post mortem morphometric data Wiggs et al 
(71) concluded that airway wall thickening and a loss of lung recoil can partially 
explain the airway hyperresponsiveness observed in patients with chronic obstructive 
lung disease and asthma. 
As discussed earlier Macklem (24) described how increased wall thickness, this time 
with the focus on the adventitial layer can affect airway constriction in response to 
stimuli. This would lead to a decreased load on the smooth muscle due to unlinking of 
the interdependence between the airway and the surrounding parenchyma. 
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Uhlig et al (72) reported a study in which airway vascular engorgement was induced 
in piglets by placing a balloon catheter in the left atrium. The effect on baseline Raw 
was modest but engorgement lead to a significantly enhanced response to 
methacholine. After engorgement, methacholine lead to a 67.8% increase in Raw at a 
dose that produced only a 10.8% increase in Raw without engorgement. Perhaps most 
interestingly the change in airway wall thickness from this process of `engorgement' 
appeared rather modest. In airways with a mean size >3mm, for example, the total 
cross-sectional area of the airway in animals with engorgement only was 3.2 mm2 
versus 2.8 mm2. The proportionate changes in smaller airways were similar. 
In a study on anaesthetized dogs Brown et al (69) investigated whether increasing 
airway wall thickness could potentiate the lumenal narrowing effect of histamine. 
High-resolution computed tomography was used to directly measure the changes in 
the caliber and wall thickness of conducting airways after histamine challenge, before 
and after airway wall thickness was increased with a normal saline volume load. 
Histamine alone reduced lumenal area to 71 % of control value, while after volume 
loading, which was noted to increase wall area, histamine reduced lumenal area to 
54% of control value. Quantitative modeling in this study indicated that the oedema in 
the airway wall was mostly outside the smooth muscle and that the smooth muscle 
shortening with histamine was similar before and after volume loading, indicating that 
the difference after volume loading was not due to enhanced smooth muscle 
constriction. The authors concluded that a moderate degree of acute airway wall 
thickening could potentiate the constrictor response to histamine. 
In a second study by the same group (70) the effects of a similar volume load using 
either normal saline or homologous blood were compared. On this occasion no 
smooth muscle constriction was induced, in fact the measurements were made after 
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administration of atropine. The normal saline increased wall thickness 150% and 
reduced lumenal area by 68%. The comparative changes following volume loading 
with blood were 108% and 81%. This suggests that rather than vascular engorgement 
it is the presence of oedema fluid in or immediately surrounding the airway wall acts 
to decrease the airway lumen in this situation. The authors go on to argue that since 
the degree of airway narrowing was only moderate, it seems unlikely that airway wall 
thickening or oedema could be a primary cause of conducting airway obstruction in 
patients with asthma or impaired left ventricular function. However Brown's earlier 
study and the model by Moreno et al (63) above clearly demonstrate that the effect of 
an increased wall thickness is primarily to potentiate the effect of smooth muscle 
shortening rather than to have a major effect on lumenal area at `baseline'. 
1.5 The relationship of the concentration of exhaled nitric oxide (NO) to the 
mechanical function of small airways and the response to bronchial challenge 
Nitric oxide (NO) plays an important role as an inflammatory mediator in the airways. 
Exhaled nitric oxide is known to be elevated in asthma (73-78) and its role as a 
marker of severity has been extensively investigated in a variety of clinical settings. 
The relationships reported to various clinico-pathological markers of asthma however 
have been somewhat variable. Many studies, in a variety of clinical contexts, have 
identified a correlation between exhaled NO and bronchial hyper-responsiveness, 
including: steroid naive asthma (76,78) and asthma associated with seasonal allergic 
rhinitis (74) as well as chronic stable asthma (79). In the context of steroid naive 
asthma exhaled [NO] has also been shown to correlate with diurnal variability in peak 
expiratory flow (PEF) (76). Although in one study NO concentration was found to 
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correlate with FEV 1(% predicted) in a large group across a broad spectrum of severity 
ranging from subjects attending the emergency department with acute severe asthma 
through chronic stable asthma to non-asthmatic controls(75), most studies show no 
significant correlation with FEV 1(% predicted) (76-78,80) other functional markers 
of severity such as symptom scores (76) or beta-agonist use (76). The reason for this 
disparity between the presence of a correlation between NO and bronchial 
responsiveness (PD20(FEVl)) yet the absence of correlation between either of these 
indices and baseline FEV 1 is not clear. 
The possible importance of the function of the small airways in determining the 
`ultimate' outcome of bronchial challenge (plateau or unlimited narrowing) is 
discussed above, as is the relatively weak relationship between this facet of response 
and baseline FEV1. Although the PD20(FEV 1) and the ultimate outcome of challenge 
are different facets of the response, the two are correlated. A relationship may 
therefore exist between the baseline function of the small airways and PD20(FEV 1). If 
so and if as reported exhaled NO is principally derived from the terminal airways (74, 
81) then this may go some way towards explaining the said disparity. I. e. exhaled NO 
may be reflecting inflammation (and thus function) of the small airways only, this in 
turn would be expected to correlate with the response to bronchial challenge yet may 
be only loosely related to indices such as FEV 1. FEV1, in the absence of significant 
airway obstruction, is probably determined principally by the function of the more 
central airways. 
It has been suggested that another pertinent factor could be the bronchoprotective role 
of NO in the context of induced bronchoconstriction. Several studies have reported 
the effect of endogenous NO on airway hyperresponsiveness when induced by a 
variety of mediators in animal models: histamine (82), bradykinin, citric acid, 
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tachykinin NKl selective antagonist and protease activated receptor 2 (83-86). Other 
studies have reported that acute bronchoconstriction induced by allergen inhalations is 
potentiated by Nitric Oxide Synthase inhibitiors (87-89). It is interesting to note that 
these molecules are primarily inflammatory mediators whose effect on smooth muscle 
constriction may indirect. Based on these in vitro and animal studies clinical 
researchers have examined the role of NO in asthma. In a randomised placebo 
controlled study Ricciardolo et al (90) found potentiation of bradykinin and 
methacholine induced bronchoconstriction after pre treatment with the NOS inhibitor, 
suggesting a bronchoprotective role for endogenous NO in mild asthma. However 
they found the effect greater with bradykinin than methacholine induced 
bronchoconstriction, which also would seem to suggest that the protective role of NO 
is mediator specific and not a direct inhibition of smooth muscle constriction. Further, 
inhaled NO has also been shown to have a small bronchodilator effect in asthma (91) 
outwith the context of induced bronchoconstriction. It would seem difficult therefore 
to explain the correlation between airway responsiveness to methacholine and exhaled 
NO together with the absence of a strong correlation between exhaled NO and 
baseline FEV1 in terms its `bronchoprotective' properties. Also, and perhaps most 
fundamentally, the direction of the correlation between exhaled NO with airway 
responsiveness would seem to run contrary to the argument that its protective role 
would explain that correlation (increased concentration of exhaled NO is associated 
with increased responsiveness). 
Thus whether the exhaled NO is simply acting as a marker of airway inflammation or 
is produced as a protective response to the airway narrowing consequent upon that 
inflammation may not be relevant to the above hypothesis. Site of production rather 
than function of NO would seem to be the crucial characteristic. 
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The relationship between baseline function of the small airways, NO, the response to 
challenge and baseline FEV 1 needs to be more formally explored. 
1.6 Summary 
The response to deep inspiration is an interesting physiological phenomenon. The 
difference in the response to DI between asthmatic and healthy subjects suggests that 
an understanding of its underlying mechanism may have some clinical importance. 
There is a general consensus that a bronchodilating response is probably mediated by 
stretch and relaxation of airway smooth muscle. The mechanism underlying the 
abnormal asthmatic response is controversial. Diminished stretch of the smooth 
muscle during DI could account for a diminished bronchodilator response however an 
additional and separate mechanism is required to explain the bronchoconstrictor 
response. 
Responsiveness to bronchial challenge is normally measured by the index 
PD20(FEVI), the dose of stimulant required to induce a 20% fall from baseline in 
FEV1. A potentially more important aspect of the response to bronchoconstricting 
stimulants however is the presence of a maximal (plateau) response or the potential 
for unlimited airway narrowing. Whilst there is some correlation between the two 
indices, the ultimate outcome of challenge cannot be predicted with certainty from the 
changes early in challenge of FEV I. This may reflect the different generations of 
airways involved in these two indices. A priori reasoning and some evidence suggest 
that the capacity for unlimited narrowing may be a function of the small airways. 
The relationship between the response to deep inspiration and the capacity for 
unlimited narrowing is interesting. The bronchodilating effect of DI in the context of 
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induced bronchoconstriction will clearly have a bronchoprotective effect. The 
maximum constriction in terms of indices of airway function not dependent on the 
effect of a deep breath (Vp, say) seems to be greater than the maximum effect as 
measured by indices dependent on the effects of DI (Vm, say). However the presence 
in some individuals of a maximal, plateau response in terms of indices such as Vp 
suggest that in these individuals at least whatever protective mechanism is limiting 
airway constriction, it is operating independently of the effects of DI. 
Of the other factors that may influence the abnormal asthmatic response to bronchial 
challenge, perhaps the most intuitively appealing is an abnormality of smooth muscle 
function. The evidence for such however is scant. Although perhaps intuitively less 
obvious, simple mathematical modeling and some evidence suggests that airway wall 
thickness may have a greater influence than previously thought. 
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Aims 
1. To determine to what degree the measured response to DI is dependent on the 
method used to assess it and to describe the relationship of that dependence. 
In chapter 4 the response to DI is assessed in terms of its effect on SGaw and forced 
expiration, the latter is reported over a range of lung volumes. 
2. To develop and test a hypothesis to explain the abnormal asthmatic response 
to deep inspiration. 
The hypothesis is developed in chapter 4 and tested in chapter 8. 
3. To re-test the hypothesis that asthmatic hyperresponsiveness is entirely due to 
impairment in the ability of inspiration to stretch airway smooth muscle. 
In chapter 5 the hypothesis tested by Skloot is re-tested using an index of airway 
function independent of both the effect of DI and the changes in EILV that are shown 
to occur as challenge progresses. 
4. To identify 'the mechanism' which imposes a limit on airway narrowing in 
healthy subjects and mild asthmatics in response to bronchial challenge. 
Assuming that, in the absence of significant bronchoconstriction, FEV1 is determined 
principally by the larger airways we reasoned that early in challenge changes in FEV 1 
probably reflect changes in calibre of the larger airways. Given their cartilaginous 
support however, narrowing of the central airways will be limited and their behaviour 
will not determine the capacity for unlimited narrowing. Thus early changes in FEV1 
may not predict ultimate outcome. This is more likely to be a function of the smaller 
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airways. In the study reported in chapter 6 this hypothesis is tested in relation to the 
ultimate outcome of challenge. The predictive power of the response of a number of 
indices of small airway function early in challenge is examined, including the index 
PD20(Vm20), the dose causing a 20% fall in the maximal flow at 20% (remaining) 
VC. The response to challenge is measured in terms of DI dependent and independent 
indices. 
5. To explore and characterize the relationship between the maximum response 
to methacholine challenge -a plateau or unlimited narrowing and: 
a. The response to DI 
b. The baseline function of the smaller airways 
c. The concentration of exhaled nitric oxide 
In chapter 7 the relationship between the response to challenge and airway function at 
baseline (pre methacholine) is examined. The response to DI, The maximum flow at 
50% FVC (Vm50) and the concentration of exhaled NO pre challenge are all 
compared with the outcome of challenge. 
The role in airway function, including the response to DI and bronchial challenge, of 
airway wall thickness and in particular the distinction between airway wall 
inflammation/oedema and the features of more chronic re-modelling are discussed in 
light of the findings in chapters 4-8. 
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Chapter 3 
Subjects and Generic Methods 
3.1 Subjects 
In total 34 control subjects and 40 asthmatic subjects were involved in the different 
studies as detailed in tables 3.1 and 3.2. All asthmatic subjects had previously 
received a diagnosis of asthma from a physician. A careful history was taken by a 
second physician at recruitment ensuring a corroborating opinion. Withdrawal of 
inhaled steroids to establish 15% bronchodilator reversibility off treatment was not 
considered necessary to the studies and was not performed. The asthmatic subjects in 
the study in chapter 7 were all steroid naive. Difficulty in recruiting such a rare subset 
of asthmatic subjects precluded such for all studies. None of the asthmatic subjects 
were taking more than 400µg of inhaled steroid (beclomethasone) per day. Normal 
subjects were all hospital employees. They reported no symptoms of asthma, had 
never received a diagnosis of asthma from a physician and had normal responses to a 
standard methacholine challenge. All subjects were non-smokers and had had no 
recent upper respiratory tract infection at the time of study. Atopic status was not 
established. Approval was obtained from the local Ethics Committee and written 
informed consent was obtained. 
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Table 3.1 Control Subjects 
subject Age sex chapter 4 chapter 5 chapter 6 chapter 7 chapter 8 
1c 33 m " " " 
2c 31 f " " 
3c 38 f " 
4c 19 f " " . " 
5c 22 m " " " " 
6c 34 m " " " 
7c 21 m " " " 
8c 26 m " " " " 
9c 43 m " " 
1Oc 35 f " 
11c 31 m " x " " 
12c 30 m " " 
13c 32 m " 
14c 38 f " " " 
15c 24 m " 
16c 33 m " 
17c 28 f " 
18c 30 f " 
19c 26 m " 
20c 25 m " 
21c 24 m " 
22c 34 m " 
23c 31 m " " 
24c 19 f " 
25c 18 f " 
26c 29 m " 
27c 25 m " 
28c 38 m " 
29c 30 f " 
30c 28 f " 
31c 27 m " 
32c 35 m " 
33c 35 f " 
34c 25 f " 
In chapter 6 `x' denotes those not included in the final analysis 
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Table 3.2 Asthmatic Subjects 
subject Age sex chapter 4 Chapter 5 Chapter 6 Chapter 7 Chapter 8 
1a 25 m " " " 
2a 20 f " " " 
3a 31 f " 
4a 28 m " " " 
5a 21 m " " " 
6a 18 f " " " 
7a 30 f " . " " 
8a 40 m " " 
9a 19 f " 
1Oa 41 f " 
11a 29 m x 
12a 28 m x 
13a 33 f " x 
14a 19 f " " 
15a 19 f " 
16a 28 m " " 
17a 28 m " " 
18a 27 f " " 
19a 30 f " " 
20a 28 m " " 
21a 30 m " " 
22a 41 f " 
23a 34 m " " 
24a 28 m " 
25a 19 m " 
26a 29 m " 
27a 27 m " 
28a 20 f " 
29a 20 f " 
30a 32 m " 
31a 29 f " 
32a 28 m " 
33a 31 m " 
34a 26 f " 
35a 34 f " 
36a 36 m " 
37a 39 f " 
38a 35 m " 
39a 41 f " 
40a 31 m " 
In chapter 6 `x' denotes those not included in the final analysis 
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3.2 Spirometric Values 
FEV 1, FVC and all derivatives of the flow volume curve (92) were measured and 
derived using the same flow sensor and software used to monitor expiratory flows 
during methacholine challenge (Sensormedics, `Vmax'). In each case the mean of 
three technically good and reproducible values was calculated 
3.3 Maximal / Partial (M/P) Ratio 
All respiratory function tests were performed with the subject seated and breathing via 
a mouthpiece attached to a flow sensor connected to specially designed software 
(Sensormedics, `Vmax'). Volume expired was derived by integration of the flow 
signal. 
The M/P manoeuvre began with tidal breathing for one minute. The volume time 
record was monitored on screen to ensure no deep breaths occurred. At the end of a 
normal tidal inspiration, (at end inspiratory lung volume, EILV) subjects performed 
the `partial' (P) manoeuvre, by forced expiration to RV. This was followed by a 
maximal inspiration to TLC. Then, without pause, the `maximal' (M) expiration, a 
forced expiration from TLC to RV, was performed. M and P flows at various 
isovolumic points were derived using software designed for that purpose 
(Sensormedics `Vmax'). Three technically good manoeuvres were obtained in each 
subject. The mean M/P ratio at each volume was calculated. 
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3.4 Specific Airway Conductance (SGaw) and SGaw ratio (pre : post deep 
inspiration) 
The measurements were performed with the subject seated and breathing via a 
mouthpiece attached to a flow sensor connected to specially designed software 
(Sensormedics, `Vmax'). Volume expired was derived by integration of this signal. 
SGaw was measured during panting at functional residual capacity (FRC) by body 
plethysmography (93,94). After panting (at a rate of between 60 and 180 breaths per 
minute), subjects performed a full inspiration followed by a full expiration for 
measurement of total lung capacity (TLC), residual volume (RV) and vital capacity 
(VC). Slope measurements were performed automatically by the `Vmax' software 
using the central portion (± 0.5 litres per second) of the flow-pressure curve. Mean 
SGaw from three technically good manoeuvres were calculated. 
The SGaw Ratio (pre : post DI) 
During tidal breathing for one minute, the volume time trace was monitored to ensure 
that no deep breaths occurred. After this DI free period SGaw, TLC, FRC and RV 
were measured. To measure `post DI' SGaw, subjects initially performed three to four 
tidal breaths in order to establish FRC. From FRC subjects then performed a maximal 
inspiration to TLC. Without pausing subjects returned to FRC as quickly as a non- 
forced expiration would permit (< 1 second) and SGaw was again measured. Mean 
SGaw from three technically good `pre DI' and 'post DI' manoeuvres were calculated. 
These two means were used to calculate the (post: pre) SGaw ratio. 
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Caveat. A very few volunteers were unable to perform the panting manoeuvre 
necessary for the measurement of SGaw. These volunteers were withdrawn 
immediately and took no part in any study that required the measurement of SGaw. 
3.5 Calibration of the Vmax System 
All calibration procedures were carried out daily before any measurements were 
made. Calibration protocols were those recommended by the manufacturer 
(Sensormedics) for the `Vmax' system. On screen instructions for calibration were 
followed. 
a. Flow -Volume Calibration 
The calibration procedure consisted of two measurements combined in one 
continuous procedure: 
1. Calibration sequence: a calibrated volume syringe (6 litres) was connected to the 
mass flow sensor and stroked 5 times to measure the volume inspired and expired by 
the syringe. The strokes were performed as smoothly and consistently as possible. The 
inspiratory and expiratory flow rates (displayed on screen) were between 3-6 Us (0.5 - 
1.0 seconds stroke duration). Correction factors were then calculated automatically by 
the software to fine-tune the volume measurement. This ensured the mass flow sensor 
measured within + 3% of the known volume of the syringe 
2. Verification Sequence: the syringe was stroked five more times and the inspired and 
expired volumes were measured using the newly calculated correction factors. 
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Differing flow rates for these strokes was permissible (between 20-720 Us). To meet 
the American Thoracic Society for high and low flow criteria for volume calibration 
at last one of the last 4 expiratory strokes had to have an average flow rate less than 
05 Us and at least one had an average flow rate greater than 3.0 Us These 
measurements made up the calibration results and were closely checked for accuracy 
against the known syringe volume. 
b. Plethysmographic Pressure Calibration 
With the cabin door closed, the procedure consisted of energising an internal 50m1 
calibration syringe that simultaneously pumped air in and out of the cabin and a small 
fixed volume chamber, thereby exposing two pressure transducers (Vbox - box 
pressure transducer and Pm - mouth pressure transducer) to known pressure /volume 
signals. Two series of sixteen strokes were displayed on screen for each transducer. 
The first stroke series was used to calculate the correction factors, the second was 
used to verify the newly calculated factors. The % targets for Vbox and Pm were 
checked to be in the range 97 -103%. If not the calibration was repeated. In addition 
to displaying the % target values, the computer evaluated the correction factors 
calculated and displayed a warning message if the factors were out of range. The 
acceptable range for Vbox was 0.7 - 1.3 (at sea level) and 0.7 - 1.3 for Pm 
(irrespective of atmospheric pressure). 
3.6 Calibration of the Mefar Dosimeter 
The principal argument for dosimetry as a mode of delivery of drug lies in its 
precision. A dosimeter is designed to deliver air at a known (and fixed) pressure for a 
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precise period of time (controllable). The air pressure is used to activate one of a 
series of nebulisers. Nebuliser output may be varied by adjusting the time of 
activation. Accurate calibration of such a system is therefore crucial. 
We purchased the commercially available Mefar MB3 dosimeter (Mefar s. r. l., 
Bovezz, Italy) supplied with 10 Mefarjet nebulisers. Each nebuliser is individually 
calibrated by the manufacturer. Results of this calibration are supplied in the form of a 
graph relating duration of activation to output, as measured by weight loss. However 
measurement of the weight loss of a nebuliser following activation does not truly 
reflect its output of aerosolized solute. Weight lost through jet nebulisation is known 
to contain two distinct components: aerosol (the reservoir drug solution suspended as 
respirable particles) and water vapor (which contains no drug solute) (95-98). 
Of these only aerosol output is of clinical relevance. Calibration based on weight loss 
will necessarily over estimate the dose of delivered drug (96). In order to calibrate the 
dosimeter we used the method designed by Dennis (96), a chemical tracer technique 
which measures true aerosol output. 
Measurement of Aerosol Output 
Aerosol output (AO) from each nebuliser was assessed using a fluoride tracer method 
(96). Four milliliters of 1% NaF solution was added to the nebuliser reservoir. The 
nebuliser was then activated through the Mefar dosimeter. The pattern of activation 
used was five 2-second bursts with a five second pause between each (a total of 10 
seconds activation). This was chosen to mimic the activation pattern that would be 
used in subsequent trials. During activation of the nebuliser, ambient air was drawn at 
15 litres / min through a fitted T- piece over the nebuliser by means of a vacuum 
pump. This entrained and impacted aerosol onto a 25mm Whatman glass fibre (GF/A) 
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filter (BDH Chemicals ltd) held within a metal cassette, held within 5cm from the 
nebuliser head. After collection filters were removed and placed in 25m1 universal 
bottles. Fluoride residues were subsequently dissolved in an appropriate buffer and 
quantified electronically as described below. Each nebuliser was activated by this 
method three times, producing three filters for separate analysis. 
Analysis of Aerosol Output 
Total Ionic Strength Adjustment Buffer (TISAB; BDH Chemicals ltd. ) was prepared 
as a 50% solution in distilled water. 20m1 was then added to each Whatman filter 
within 25m1 plastic universal bottles. The bottles were then sealed and flouride was 
allowed to desorb overnight. The recovery of fluoride from filters was complete 
(>98%) and no fluoride was detected in unused filters. Fluoride analysis followed 
well established protocols (99). Fluoride standards were prepared by microlite 
injections of 20.0,50.0,75.0 and 100.0 micro-litres of 1.00% NaF into 20m1 aliquots 
of 50% TISAB, resulting in 2.38 x 10'4M, 5.95 xl O-4M, 8.93 xl O4M, 1.19 X 10-3M 
fluoride solutions. Both standard and test solutions were equilibrated to 25°c in a 
water bath. Flouride concentrations within the buffered solutions were then measured 
electrochemically with a fluoride specific ion electrode (Corning Ltd, Halstead) on a 
Corning 225pH / ion meter with a calomel reference electrode. This electro-chemical 
system had a log linear relation between concentration and activity (mV) from 10"1 M 
to 10-6 M. All solutions were continually agitated during analysis with an 
electromagnetic stirrer. An internal four-point calibration was established. The 
standard curve was used to quantify all test solutions and reported directly the 
microlite of aerosol fluoride impacted on and desorbed the test filters. The error of 
fluoride determination was within 2%. 
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Results 
Output of each nebuliser unit (µl) of solution for each '10 second activation' in a 
series of 3. 
nebuliser 1 2 3 average 
1 61.3 64.9 61.4 62.53 
2 65.7 64.6 67.2 65.83 
3 57.9 78 79.5 71.8 
4 68.8 63.7 72.1 68.2 
5 56.1 80 76.7 70.93 
6 85.6 56 66.4 69.33 
7 74.5 72.6 66.6 71.23 
8 63.4 63.3 63.6 63.43 
9 66.6 67.7 67.1 67.13 
10 80.3 77 78.8 78.7 
average 68.91 
Calculation 
Using these results one could calculate the total activation time in seconds (usually 
delivered in 5 equal activations) to deliver 50µ1 of solute (l0µ1 per activation) for 
each nebuliser unit individually. To fully utilize the precision in this data requires a 
software driven nebuliser capable of being programmed with different activation 
times for each stage of challenge. Alternatively the average may be used to calculate 
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an average activation time to be used for all stages of challenge. 
Methacholine Stock and Diluents 
Methacholine Chloride was obtained in chrystalline form from ACIC (Canada) Inc., 
in quantities of 100g. The crystals are hygroscopic and so were kept in a sealed 
container in a freezer. A stock solution of 64mg/ml (with phenol 0.4% as a 
preservative) was supplied by the hospitals pharmacy. It was kept in a sealed 
container in a refrigerator in the lab. At this dilution it has a shelf life of 4 months. 
The pharmacy also supplied 2 diluents: Diluent A (sodium bicarbonate 0.275% and 
phenol 0.4%), Diluent B (sodium chloride0.8%, sodium bicarbonate 0.275% and 
phenol 0.4%) 
Preparation of Methacholine Solutions 
The standard test requires the preparation of 10 doubling concentrations of 
methacholine chloride from 0.0625mg/ml to 32 mg/ml, in 10 separate test tubes 
labelled 1-10, in volumes of 4m1 each, using the stock solution of methacholine with 
diluents A and B. The following protocol was used: 
1. Ensure the test tubes are clean and dry before use. 
2. Place test tubes in rack labelled 1-10 left to right. 
3. Replace filter in `Pipetteman' auto pipette. 
4. Check pipette ends are clean and dry 
5. Set pipette to desired number, usually 4ml (this should be checked repeatedly 
during the procedure). 
6. Put 4m1 methacholine stock solution in tube 10. Change pipette end. 
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7. Put 4m1 diluent Ain tube 10 (this reduces acidity and osmolality towards 
physiological levels). Cap and mix well. Change pipette end. 
8. Put 4m1 diluent B in tubes 1-9 (this maintains pH and osmolality near to 
physiological levels). Check volumes. Change pipette end. 
9. Take 4 ml from tube 10 and place in tube 9. Cap and mix well. 
10. Take 4m1 from tube 9. Fill and empty pipette 2 or 3 times to flush pipette end, 
then place 4m1 in tube 8. 
11. Repeat step 10 to provide serial 2-fold dilutions in the remaining tubes. 
12. Check volumes of solutions in tubes. If there is an obvious difference between 
tubes start again. 
13. Label test tube rack with date and check test tubes are labelled correctly. 
14. Unused solution at the end of that day was discarded. 
Bronchial Challenge 
Bronchial challenge is an important diagnostic test finding increasing use in clinical 
practice. It is a measure of'airway responsiveness'. The test involves doubling 
incremental doses of the bronchoconstricting drug, methacholine (or histamine) 
sequentially delivered as aerosol. The standard regimen starts with an initial dose of 
3.125mcg and proceeds to a possible standard maximum of 6,400mcg. 
Pre test baseline respiratory function is established (usually FEV1). After each dose is 
delivered, this measure is repeated. A graph of response (fall in FEV1) vs. dose of 
methacholine can then be plotted (graph 3.1). 
The most commonly used index of bronchial reactivity is the PD20, the dose of drug 
producing a 20% fall in respiratory function (FEV1), a value interpolated from the 
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above graph. Other specific points of note however would include: (i) threshold of 
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3.7 Methacholine Challenge (dosimeter method). 
As used in chapters 5 and 6 
Subjects performed a modified version of a standard methacholine challenge (100). 
Methacholine aerosol was administered in doubling cumulative doses (3.125 to 6,400 
µg) from a Mefar dosimeter at 5-minute intervals until a 40% decrement in FEV 1 was 
recorded or the dose sequence completed. The aerosol was released electronically 
(using a thermistor) in 10 µl (± 10%) aliquots over 1.5 seconds as the subject began to 
inhale from end tidal expiration. He/she continued to inhale for a further 4 seconds 
after aerosol delivery. If full inspiration was achieved earlier, breath holding 
53 
completed this 5.5 second period. Five aliquots inhaled in rapid succession comprised 
a single challenge dose, further doses being administered at 5-minute intervals. Each 
dose was administered immediately on completion of the measurements following the 
previous dose. After each dose of methacholine subjects were asked to avoid taking a 
deep breath. A period of approximately 4 minutes elapsed between the last deep 
inspiration associated with methacholine administration and measurement of airway 
function. During the final minute prior to measurement tidal breathing was monitored 
with the subject breathing through a flow sensor to confirm the absence of DI. 
Subjects then performed a forced expiration from the end of a normal tidal inspiration 
to residual volume (RV) - the `partial' (P) expiration. This was followed by a 
maximal inspiration to TLC. Then, without pause, the `maximal' (M) expiration, a 
forced expiration from TLC to RV, was performed. Assuming that TLC did not 
change (101,102) this allowed measurement of flow at the same absolute lung 
volume at each stage of challenge. The standard protocol by Beach et el has a high 
degree of precision with the co-efficient of repeatability of 3.0 (using the statistical 
method described by Bland and Altman (103)). The requirement for a consistent DI 
free period and time interval from delivery of methacholine to a `partial' expiration 
limited the number of `M/P' manoeuvres to one at each stage of challenge. This 
limitation is likely to reduce the reproducibility of the test. For each index of lung 
function the cumulative dose provoking a 20% fall from its baseline value (PD20) 
could be calculated. 
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Dose Regimen 








1 5 0.0625 3.125 3.125 
1 5 0.0625 3.125 6.25 
2 5 0.125 6.25 12.5 
3 5 0.25 12.5 25 
4 5 0.5 25 50 
5 5 1 50 100 
6 5 2 100 200 
7 5 4 200 400 
8 5 8 400 800 
9 5 16 800 1600 
10 5 32 1600 3200 
10 10 32 3200 6400 
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3.8 Methacholine Challenge (tidal breathing method). 
As used in Chapter 7 
Although careful monitoring of what were felt to be appropriate DI free periods had 
occurred in the studies in chapters 5 and 6, the involvement of DI in the 
administration of methacholine in a study in part designed to assess the response to DI 
seemed illogical. Thus, at the suggestion of my supervisor, for the study in chapter 7 
an alternative (tidal breathing) protocol was adopted. 
The method used was modified from the protocol by Juniper et al. (104). This method 
is reported to be less precise, i. e. has a higher co-efficient of repeatability, than the 
dosimeter method (10.9 vs. 3.0) (100,103). But the difference is thought to be due to 
the difference in quantifying FEV 1 in the standard protocols. In the modified protocol 
used, as in the dosimeter protocol, the requirement for a consistent DI free period and 
time interval from delivery of methacholine to a `partial' expiration limited the 
number of manoeuvres to one at each stage of challenge. This factor is likely to be 
most important in determining reproducibility. 
Methacholine aerosol was administered in doubling concentrations (from 0.03125 to 
16mg/ml) from a nebuliser unit (Mefar) with mouth piece, driven by a `Pan 
TurboBoy' Compressor delivering compressed air at 40psi. Subjects wore nose clips 
throughout the challenge protocol. For the delivery of each concentration subjects 
were instructed to relax and breathe quietly (tidal breathing) and to avoid any deep 
breaths. A respiratory inductance plethysmograph ('respitrace', Studley Data 
Systems, Oxford. Model 250), which was worn throughout the challenge protocol, 
was used to monitor the absence of deep breaths. 
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Subjects breathed each concentration for precisely 2 minutes. After methacholine 
delivery subjects transferred to the mouth piece and flow sensor (monitoring flow and 
volume derived by integration). Subjects first performed a further 90 seconds tidal 
breathing, the avoidance of deep breaths being monitored on screen. Thus ensuring a 
total of 3.5 -4 minutes without DI. At the end of a normal tidal inspiration, (at end 
inspiratory lung volume, EILV) subjects performed the `partial' (P) manoeuvre, by 
forced expiration to RV. This was followed by a maximal inspiration to TLC. Then, 
without pause, the `maximal' (M) expiration, a forced expiration from TLC to RV, 
was performed. M and P flows could then be extracted at any lung volume using 
software designed for that purpose (Sensormedics `Vmax') (figure 3.2). Assuming 
that TLC did not change (101,102 ) this allowed measurement of M and P flow at the 
same absolute lung volume at each stage of challenge. Finally two further FEV 1 
manoeuvres were performed allowing measurement of the response to challenge by 
this standard index. 
Subjects then return immediately to inhalation of Methacholine at the next 
concentration. Challenge continued until a 20% fall in FEV1 or the dose sequence 
was completed. For each index of lung function the concentration of methacholine 






3.9 Exhaled Nitric Oxide Concentration (NO) 
Using a commercially available (Logan Research LR 2000 series) chemiluminescence 
analyser, subjects exhaled slowly from total lung capacity at a constant flow rate. This 
is determined by the inherent resistance in the system and a voluntarily maintained 
mouth pressure of 40mmH2O monitored visually on screen by the subject. This 
pressure ensures closure of the soft palate and precludes nasal air leak. The 
concentration of exhaled CO2 was also monitored on the same time plot on screen. 
The concentration of exhaled NO (ppb) corresponding to the start of the plateau of 
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VOLUME 
exhaled CO2 was recorded. The mean of 3 technically good values was calculated. 
The method is as per the manufacturer's instructions and follows the 
recommendations of Kharitonov et al (105). 
Calibration of the NO analyzer: 
Calibration was carried out after the analyzer had been switched on for at least 30 
minutes. It was performed using the automated (software driven) calibration protocol 
and a standard calibration gas. The measured value had to reach the known 
concentration of NO within 30 seconds and be stable. 
Calibration of Mouth Pressure: 
The automated (software driven) calibration protocol was followed. The pressure was 
`zeroed' during the `zero' phase of the protocol, then using a pressure source in the 
form of a water manometer U tube a stable pressure was connected to the transducer. 
A standard pressure of 50.0 mmH2O was used. The software automatically adjusted 
the calibration factor. The pressure was then removed from the positive pressure port. 
3.10 Statistical Analysis 
All statistical analysis was performed using a commercially available software 
package 'SPSS 10.0 for Windows'. All between group comparisons were made using 
either a paired or unpaired (as appropriate) two-tailed Student's t test. Comparisons 
with unity, as in the case of M/P ratio at a given lung volume in chapter 4, was done 
using a one sample Student's t test. 
All correlations were performed using Pearson's Correlation Coefficient. 
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In the case of methacholine challenge results, all `provoking dose' indices were 
logarithmically transformed before inter group comparisons were performed. 
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Chapter 4 
The Apparent Response of Airway Function to Deep Inspiration Depends on the 
Method of Assessment 
INTRODUCTION 
The response to DI in asthmatic and non-asthmatic subjects is reported to be different 
in most published studies. However there is also considerable variability in the 
reported response to DI within each of these subject groups. A variety of methods 
have been used to assess the response to DI. The purpose of this study is to determine 
to what degree the measured response to DI is dependent on the method used to assess 
it and to describe the nature of that dependence. 
In the study the response to DI is assessed in terms of its effect on SGaw and forced 
expiration, the latter over a range of lung volumes. The findings are discussed and the 
implications for any putative mechanism to explain the `bronchoconstrictor' response 
to DI in asthmatic subjects are considered. 
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METHODS 
Subjects and methods 
We studied 16 mildly asthmatic and 16 normal subjects of similar age (tables 3.1- 
3.4 and summarised in table 4.1). 
All respiratory function tests were performed with the subject seated and breathing via 
a mouthpiece attached to a flow sensor (Sensormedics). M/P ratio, SGaw and SGaw 
ratio (post: preDI) were measured by the methods described in chapter 3 (sections 3.3 
& 3.4). 
Protocol 
After initial consent and measurement of FEV 1 and VC, all tests were performed the 
following day. All subjects followed an identical protocol in the order: (1) M/P ratio, 
(2) SGaw (pre DI) and (3) SGaw (post DI) according to the methods described in 
chapter 3. 
In each of these three indices the mean of three technically good values was recorded. 
There was a 5-minute time interval between the final measurement of M/P and the 
first measurement of SGaw. After the final measurement of SGaw (pre DI) subjects 
proceeded immediately to the measurement of SGaw (post DI). 
The five minute interval between the measurement of M/P and the start of the SGaw 
(pre DI) manoeuvre plus the one-minute monitored `DI free' period integral to this 
measurement I felt minimised the potential for any residual effect from the preceding 
manoeuvre on the measurement of SGaw. Lest there be however, the order was 
identical in all subjects so that any (theoretical) order bias would not differ between 




The M/P ratios were compared to unity at each lung volume (40,35,..., 15%VC and 
FRC) in each group using, one sample Student's t test. The M/P ratios in the 
asthmatic and control groups were compared at each lung volume using unpaired t 
tests. The mean M/P ratio at each lung volume was plotted against lung volume 
(%VC) for asthmatic and healthy subjects separately. The association between lung 
volume and M/P ratio was assessed by Pearson's Correlation Coefficient. 
SGaw Ratio 
The SGaw (post: pre DI) ratio in both the asthmatic and control groups was compared 
with unity using one-sample t tests. A comparison between the two groups was 
performed using an unpaired t test. 
M/P compared with SGaw ratio. 
Correlations were examined between the SGaw ratio and M/P ratio at each lung 
volume (40,35,..., 15%VC and FRC ), in each group and the two groups combined. 
Caveat 
The relative novelty of the indices used in this study and the lack of clear previously 
published data on repeatability made power calculations prior to study design 
difficult. I did not set out to formally establish an index of reproducibility thus this 
remains essentially unknown. The natural volatility in any index based on a ratio 
suggests the inherent `noise' in the signals may be high. The study was therefore 
probably prone to `type two' statistical errors. Thus, although any statistically 
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significant finding is likely to be valid, the finding of the absence of a statistically 
significant relationship should be interpreted with caution. 
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RESULTS 
The relationships of M/P ratios to lung volume (Fig 4.1) show the following features: 
(i) M/P ratio increased significantly and systematically as lung volume decreased 
in both subject groups. 
(ii) The M/P ratio was greater than one at most lung volumes in both groups. However 
only at lower lung volumes (25,20 and 15%VC in asthmatics, 20 and 15%VC in 
healthy controls) was the difference from unity statistically significant. 
(iii) At each of the lung volumes 40,35,..., 15%VC (fig. 4.1) and FRC (fig. 4.2) the 
mean M/P ratio was (non-significantly) greater in the asthmatic than the healthy 
subjects. 
In contrast to the M/P ratios the mean SGaw ratio (fig. 4.2) was greater in the healthy 
than the asthmatic subjects (p=0.005). Indeed in both asthmatic and healthy groups 
the SGaw (post: pre DI) ratio contrasted with the M/P ratio measured at the same lung 
volume (FRC). In the asthmatic group SGaw ratio was less than 1 (p = 0.049), 
suggesting bronchoconstriction in response to DI, mean (sem) = 0.938 (0.029). In 
healthy controls the SGaw ratio was greater than 1 (p = 0.048) suggesting 
bronchodilatation in response to DI, mean (sem) = 1.063 (0.029). 
Relation between SGaw ratio and M/P ratio (Table 4.2, Figs. 4.3a & 4.3b) 
In healthy subjects the correlations between SGaw ratio and M/P ratio at each lung 
volume as well as with the mean M/P ratio over the various lung volumes investigated 
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(40,..., 15%VC) were statistically significant (Table 4.2 and fig. 3b). At FRC the 
correlation just failed to reach conventional significance. In asthmatic subjects by 
contrast, no significant correlation was found at any lung volume or with mean M/P 
(40,..., 15%VC) (Table 4.2 & fig 3a). 
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Table 4.1 
Baseline Characteristics of Subjects 
Age FEV 1 FEV 1 SGaw$ %VC 
% predicted remaining at 
FRCt 
Mean (sd)* Mean (sd) Mean (sd) Mean (sd) Mean (sd) 
Asthmatic 27.9 (8.3) 3.63 (0.91) 94 (12.8) 0.10 45.2 
(0.03) (10.3) 
Healthy 27.5 (5.9) 4.35 (0.87) 102 (8.6) 0.15 42.8 
(0.05) (8.1) 
p value 0.87 0.03 0.03 0.008 0.46 
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DISCUSSION 
In assessing the airway response to DI several authors have used SGaw ratio (post : 
pre DI) (1,4,5,14-16,18-20) while others have used M/P ratio. In addition the latter 
has been reported at different lung volumes (25 to 50 %VC remaining) in different 
studies (3-11). In two studies the response to DI has been assessed by both indices in 
the same subjects but with conflicting results. Lim et al (5) found that changes in 
SGaw were qualitatively consistent with changes in maximum flow (M/P ratio) in 
asthmatic subjects. By contrast Burns et al (4), also studying asthmatic subjects, found 
divergence between these two indices, with M/P >1 but reduced SGaw post DI. 
Furthermore it is noteworthy that most studies in asthmatics using M/P report an 
apparent bronchodilator response to DI (M/P >1) (6-11), whilst those using SGaw 
suggest that DI has a bronchoconstricting effect. (5,15,16,18,19). Similarly in the 
present study the asthmatic subjects showed apparently paradoxical findings. Mean 
SGaw ratio suggested bronchoconstriction post DI, yet mean M/P ratio, at the same 
lung volume, suggested bronchodilatation. The healthy subjects in this study showed 
the converse pattern, with SGaw ratio suggesting bronchodilatation and M/P ratio 
suggesting bronchoconstriction. 
The M/P Ratio 
These results clearly show that M/P ratio varies in a systematic way with the volume 
at which it is measured, increasing as lung volume decreases both in asthmatic and 
healthy subjects. This is consistent with the findings of Pellegrino et al (106) who 
measured M/P at three lung volumes (30,40 & 50%VC) and found that it increased as 
volume (remaining) declined. 
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I have considered three possible explanations for this finding: 
(i) Gas compression artefact. 
During forced expiration gas within the thorax undergoes compression. The 
measurement of expired volume during forced expiration can therefore underestimate 
the change in thoracic gas volume. In the M/P manoeuvre the `M' and the `P' 
expiratory traces are positioned in relation to each other and the volume axis on the 
basis of the expired gas volume. Given the compression already present within the 
thorax during `maximal' expiration at the point which appears to be isovolumic with 
EILV - the lung volume at which the `partial' expiratory manoeuvre was begun, the 
actual thoracic gas volumes on the two curves, at this point at least, are likely to be 
different. Also the degree of compression will depend on the volume of gas within the 
thorax and indeed the pressure generated. The degree of the underestimation will 
therefore vary as lung volume varies during the forced expiratory manoeuvres. Thus 
this `error' in assessing lung volume using expired gas volume may result in a 
systematic error in the M/P ratio which itself may vary with lung volume. This 
`compression artefact' may theoretically have explained our findings in relation to 
M/P and lung volume, however two previous studies (106,107), which included 
values based on plethysmographic measurement of lung volume (TGV) as the 
reference as well as expired volume suggest that the findings are not attributable to 
gas compression artefact and though based on more limited data, the findings of 
plethysmographic measurements (107) in both healthy and asthmatic subjects suggest 
a similar inverse relationship between M/P and lung volume (TGV) to that reported in 
the present study. 
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(ii) A mathematical consequence of the change in RV. 
Previous studies (9,11,106,108) have shown, and I have confirmed, that when DI 
increases expiratory flows, FVC also increases, i. e. RV following the maximal 
expiratory manoeuvre is less than `RV' following the partial manoeuvre. It is clear 
therefore, particularly in the case of healthy subjects when the descending limb of the 
flow-volume relationship is essentially straight, that it is a geometric impossibility for 
the M/P ratio to be constant at different volumes i. e. volume dependence of the M/P 
ratio inevitably accompanies a shift of the maximal expiratory curve to the right of the 
partial curve. This explanation however, merely tells us that M/P must be volume 
dependent; it offers no insight into the mechanism. 
(iii) Generational differences in the airways. 
Theory suggests that the lower the lung volume, the greater the dependence of 
maximum expiratory flow on peripheral airway calibre (109). Thus dependence of 
M/P on lung volume might reflect a differing effect of DI on different generations of 
airway, with the larger airways showing relatively less bronchodilatation. There is 
evidence that the stretch associated with DI causes a temporary reduction in smooth 
muscle tone. This effect is consistent with the enhanced bronchodilating effect of DI 
seen in the context of methacholine induced bronchoconstriction in both asthmatic (4- 
6,17) and healthy subjects (1,8) and with diminution of the bronchodilating effect of 
DI following administration of ß2 sympathetic agonists (6,16,23). The greater 
cartilaginous support of the more central airways may result in less smooth muscle 
stretch during DI than would occur peripherally and thus less relaxation post DI. This 
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would result in relatively less dilatation of the larger airways and a lower M/P ratio at 
higher lung volumes. 
SGaw Ratio 
In healthy subjects mean SGaw increased after deep inspiration, while in the 
asthmatic subjects it decreased, findings that are in accord with most previous studies. 
DI may stretch asthmatic airways less effectively, either because of a change in the 
smooth muscle structure or behaviour or because airway wall inflammation and 
oedema uncouples the interdependence between the airway and the surrounding 
parenchyma (24). However, this would account only for a diminution in the 
bronchodilating effect of DI, and not for frank bronchoconstriction. Hysteresis of the 
lung parenchyma of relatively greater magnitude and acting in opposition to hysteresis 
of the airway has been proposed as the mechanism to explain bronchoconstriction 
post DI in asthmatic subjects (4,7,14,23,29). While this would account for a 
reduction in SGaw post DI in asthmatic subjects, it would not explain the apparently 
paradoxical increase in forced expiratory flow observed in the same subjects. Thus 
differential hysteresis of airways and parenchyma cannot account for all reported 
observations. 
Comparison of the responses to DI as measured by M/P ratio and SGaw ratio. 
At first sight the response of the airways to DI as measured on the one hand by SGaw 
ratio and on the other by the M/P ratio would appear to be contradictory in both the 
asthmatic and healthy groups. For comparison with SGaw ratio the most appropriate 
volume at which to measure M/P would seem to be FRC (the lung volume at which 
SGaw is calculated). In the asthmatic subjects the mean M/P at FRC was greater than 
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one, whereas the mean SGaw ratio was less than one. In the healthy subjects, the 
reverse situation applied, mean M/P ratio was less than one, yet mean SGaw ratio was 
greater than one. Clearly therefore the factors that determine the effect of DI on SGaw 
must differ from those which determine the change in forced expiratory flow. The 
different conditions under which airway function is assessed by these two methods 
may explain the apparent paradox. SGaw is a measurement of airway function in the 
'unstressed' state, while forced expiratory flow depends on both unstressed airway 
dimensions and compliance of the airway wall, which determines its ability to 
withstand the large compressive forces occurring during forced expiration. 
If as well as narrowing following DI, asthmatic airways were to become more rigid 
they would resist compression during forced expiration, which would tend to increase 
expiratory flow, particularly at lower lung volumes, despite a reduction in SGaw. The 
net result on forced expiratory flow would therefore depend on the relative 
contribution of these two factors. With a sufficient reduction in airway compliance 
post DI, forced expiratory flow could increase despite marginal narrowing of the 
unstressed airway. 
In healthy subjects (where SGaw ratio >1 yet M/P was less than in the asthmatic 
subjects) increased compliance of the airway wall consequent on smooth muscle 
relaxation post DI would tend to reduce forced expiratory flow. The same mechanism 
may operate, albeit to a lesser degree in asthmatic airways but a further mechanism is 
required to explain the observed post DI bronchoconstriction (SGaw ratio <1) as well 
as the hypothesised increase in airway wall rigidity post DI (leading to M/P >1). 
In healthy subjects the strong positive correlation between M/P and SGaw ratio (Table 
4.2, fig 4.3) suggests the absence (or relative insignificance) of any such additional 
mechanism. On the other hand, a marked lack of correlation between M/P and SGaw 
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ratio was noted in the asthmatic group. This suggests an additional, DI-related 
mechanism, which varies independently of the DI induced change in smooth muscle 
tone. Both this hypothesised mechanism and the change in smooth muscle tone post 
DI may each affect unstressed airway calibre (and hence SGaw) and airway wall 
rigidity, but if so their respective contributions would have to differ quantitatively. 
In addition to smooth muscle stretching therefore, if a single further mechanism is to 
account for all of the observed effects of DI it must satisfy a number of conditions: 
(i) It must account for bronchoconstriction post DI in asthmatics. 
(ii) It must account for an increase in airway wall rigidity post DI in asthmatics. 
(iii) It should be distinct from, and thus vary independently of, smooth muscle 
stretch/relaxation. 
(iv) It should be absent or insignificant in healthy subjects. 
According to the relative hysteresis hypothesis (4,7,14,23,29), greater hysteresis of 
the parenchyma than the airways in asthma results in bronchoconstriction post DI 
(SGaw<1). However parenchymal hysteresis results in lower lung recoil pressure post 
DI and would lessen the retractile force on the airway wall. This would render the 
airway more, rather than less, susceptible to compressive forces during forced 
expiration, thus condition (ii) is not satisfied. 
As an alternative explanation of the disparate findings of the effects of DI in this and 
other studies I propose the following hypothesis: 
A large proportion of the increased thickness of the airway wall in asthma is due to 
inflammation, which includes: increased vascularity, leaky capillaries, inflammatory 
exudate and oedema. Even in stable situations the equilibrium of intra /extra vascular 
78 
fluid flux is dynamic and delicately balanced. This equilibrium could clearly be 
altered by the large, negative intra thoracic pressure generated during a rapid deep 
inspiration. Such pressure applied to a leaky, low-pressure capillary bed would cause 
a net extravasation of fluid into the airway wall, increasing its thickness and reducing 
its lumen (and thus reducing SGaw). The increased interstitial fluid would also render 
the airway wall more turgid, reducing its compliance as recently reported with airway 
wall inflammation in vitro (110,111). Consequently the airway would be less 
susceptible to compressive forces during the subsequent forced expiration. As this 
putative effect is distinct from DI induced smooth muscle stretch, it may account for 
the lack of correlation between the M/P and SGaw ratio in asthmatic subjects. In 
healthy subjects without inflammatory changes such a mechanism would be absent or 
insignificant. 
In summary, therefore, DI associated reduction in smooth muscle tone due to 
stretching is likely to occur in both healthy and asthmatic subjects, although there is 
evidence that this effect may be diminished in asthma. A reduction in smooth muscle 
tone would tend to dilate the unstressed airway and reduce airway wall rigidity. This 
would increase SGaw but the effect on forced expiratory flow would be determined 
by the relative magnitude of these two opposing effects. I suggest that in inflamed 
asthmatic airways extravasation of fluid during DI would reduce lumenal diameter 
and therefore SGaw but at the same time it would increase airway wall rigidity and 
thus tend to increase forced expiratory flow post DI. 
The response of maximal flow and SGaw to DI in any individual asthmatic subjects 
would then be the net result of the effects of the reduction of smooth muscle tone and 
fluid flux in the airway wall. 
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In conclusion the observed response to DI clearly depends on the method of 
assessment. Thus the simple descriptors `bronchodilatation' and `bronchoconstriction' 
are inadequate to describe that response fully. These findings are clearly of practical 
importance to future studies of the effect of deep inspiration on airway function. In 
addition, the dependence of airway function on both the lung volume and the method 
of assessment may be of broader interest as it may provide insight into the 
pathophysiology of the asthmatic airway. 
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Chapter 5 
Airway Hyperresponsiveness in Asthma: Not just a problem of smooth muscle 
relaxation with Inspiration. 
INTRODUCTION 
The relative attenuation of the bronchodilating effect of DI seen in asthmatics led Fish 
et al (13) to hypothesise that hyperresponsiveness in asthma is caused by impaired 
ability of inspiration to stretch airway smooth muscle. Skloot et al (9) reasoned that if 
this hypothesis were true, the sensitivity to inhaled methacholine of normal and 
asthmatic subjects should be the same if the challenge was carried out under 
conditions where deep inspiration was prohibited. They performed methacholine 
challenge under such conditions in asthmatic and control subjects and found no 
apparent difference in the responses of the two groups. There are theoretical 
reservations that their index of bronchoconstriction may obscure differences between 
the responses of the two groups. The hypothesis is re-tested using an index not prone 
to such an error. 
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SUBJECTS AND METHODS 
I studied 10 mildly asthmatic and 10 normal subjects (tables 3.1-3.2 and 5.1). 
Subjects performed a modified version of a standard methacholine challenge as 
described in chapter 3 (3.6 Methacholine Challenge - dosimeter method). As 
described earlier, the requirement for both a consistent DI free period and a standard 
time interval from delivery of methacholine to measurement of expiratory flow 
limited the number of `partial' manoeuvres to one at each stage of challenge. 
As the volume at which subjects commenced their partial expiration inevitably varied, 
the lung volume (expressed as percentage baseline VC) at which `partial flow' (Vp) 
was measured was selected such that in all subjects at all stages of challenge, the 
partial expiration was commenced above that point. The greatest volume that 
satisfied this condition was 35% baseline VC (65% expired). The expiratory flow at 
this volume during a partial expiration, Vp35, was extracted using software linked to 
the flow sensor (Sensormedics, Vmax). In addition I calculated the index r used by 
Skloot et al (9) (defined as: FET25_75 / 1n3, where FET25_75 is the time to expire the 
middle 50% of the partial VC) from the same forced partial expiratory manoeuvres. 
The volume at the end of tidal inspiration (EILV) just prior to the forced partial 
expiration was determined as a percentage of baseline VC using the subsequent TLC 
as a reference point. 
All controls completed the challenge sequence up to a total cumulative dose of 
6,400µg methacholine. For a number of the asthmatic subjects the challenge was 
terminated by a 40% fall in FEVI before the dose sequence was complete. The 
highest delivered dose common to all subjects (asthmatics and controls) was 50 µg. 
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Comparison of response between the two groups was therefore made at this dose. All 




As expected, there was a clear difference in the standard response to challenge as 
measured by FEV1 between the two groups. In addition however, the highly 
significant difference in response as measured by Vp35 shows that even in the absence 
of DI the asthmatic subjects were more responsive. The difference in response as 
measured by the ti index, which had been derived from the same forced expiratory 
manoeuvres as Vp35, failed to reach statistical significance. I found a greater rise in 
EILV and RV between baseline and 50µg methacholine in asthmatics than controls. 
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Table 5.1 
Baseline Characteristics of Subjects 
Age 
Mean (sd) 
FEV 1(% pred) 
Mean (sd) 
FEV 1 PD20 
Median 
Asthmatic 28.4 (6) 96.6 (11.0) 128 gg 
Control 29.0(6) 101.2 (10.0) 
>6400gg 
Characteristics of subjects including response to methacholine challenge as measured 
by FEV1 PD20, the provoking dose causing a 20% fall in FEV 1 from baseline. 
85 
Table 5.2 
Measurements pre challenge and after inhalation of 50 µg methacholine 
Asthmatic Control value 
FEV1 (1) 3.53 (0.81) 4.21 (0.83) 0.082 
baseline 
FEV1 (1) 2.86 (0.92) 4.03 (0.71) 0.006 
post Mch 
FEV1 post Mch, 80.6 (16.8) 96.5 (6.7) 0.018 
% baseline 
Vp35 (1s') 2.25 (0.90) 3.40 (1.08) 0.019 
baseline 
Vp35 (IS-1 0.44 (0.41) 2.52 (1.33) 0.0008 
post Mch 
Vp35 Post Mch, 25.9 (27.8) 72.1 (21.8) 0.0007 
% baseline 
ti (s) 1.06 (0.43) 0.64 (0.20) 0.014 
baseline 
ti (s) 2.79 (1.44) 1.17 (0.65) 0.007 
post Mch 
ti post Mch, 277 (139) 184 (60) 0.075 
% baseline 
A EILV 15.0 (13.2) 2.4 (6.9) 0.019 
(% baseline VC) 
ARV 15.1 (13.7) 1.49 (6.54) 0.015 
(% baseline VC) 
Between group comparisons in terms of FEV1, the partial flow at 35% baseline VC 
(Vp35) and r. Baseline values, values after a dose of 50 µg Mch and response (post 
Mch values as a% of baseline value) are shown. Values are mean (sd). RV in this 
table relates to RV at the end of partial expiration. 
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DISCUSSION 
The hypothesis under investigation is that `asthmatic hyperresponsiveness is due to a 
problem of smooth muscle relaxation with deep inspiration' (9). This idea was first 
mooted by Fish et al in 1981(13). At the heart of the hypothesis is that the asthmatic 
and healthy responses to DI differ. Fish et al compared the effect of DI on 
methacholine induced bronchoconstriction in asthmatic and non-asthmatic subjects. 
The reduction of airway resistance following DI in controls was less or absent in 
asthmatic subjects. The results were attributed to a failure, in asthmatic subjects, of DI 
to stretch (and relax) airway smooth muscle. Subsequently, a number of authors have 
investigated the response to DI in asthmatic subjects. While attenuation of the 
bronchodilator effect in asthma has been a common finding (5,6,16,17) several 
authors have found a bronchoconstrictor effect of DI in some asthmatics, particularly 
the more severe (3,5,6,16,17,19,112). Such findings do not contradict Fish's 
proposed mechanism but cannot be entirely explained by it, as an additional 
mechanism to account for the bronchoconstriction is required. The mechanism(s) 
involved have been the subject of much debate. No final consensus has been achieved 
though some data support a mechanism involving an altered balance between airway 
and parenchymal hysteresis (7). Whatever the mechanism, the diminution (or 
reversal) of the bronchodilating effect of DI on induced bronchoconstriction in 
asthmatics implies that if DI is prohibited the difference in responsiveness between 
asthmatic and normal subjects is inevitably reduced. It is therefore important to 
determine whether, in the absence of DI, there is complete loss of asthmatic 
hyperresponsiveness or only the relative diminution, which would be predicted by 
previous studies. Only complete loss would support the revised (and more limited) 
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hypothesis that: hyperresponsiveness in asthma can be accounted for entirely by the 
altered response to DI. 
Studies (45-47) using specific airway conductance (SGaw) as the index of airway 
function have consistently shown hyperresponsiveness in asthmatic subjects. In 
principle such measurements are independent of DI but it is not clear from these 
papers to what extent, if any, DI was prohibited prior to the measurement of SGaw. 
The influence of any preceding DI therefore could not be excluded. 
In the present study I have measured the responses of asthmatic and control subjects 
to methacholine in the absence of DI. 
All controls completed the challenge sequence up to a total cumulative dose of 
6,400µg methacholine. For a number of the asthmatic subjects the challenge was 
terminated by a 40% fall in FEVI before the dose sequence was complete. The 
highest delivered dose common to all subjects (asthmatics and controls) was 50 µg. At 
this dose the mean fall in FEV1 in the control group was only 3.5%. However even at 
this relatively early stage of challenge this was statistically different to the mean 
asthmatic response (19.4%). At issue is whether in the absence of the effect of DI the 
asthmatic and control responses would be the same. 
To test this requires an index of bronchoconstriction that is independent of both the 
effects of DI and any change in EILV that occurs as bronchoconstriction progresses. 
My results show that the latter is relevant as a greater increase in EILV during 
challenge was seen in the asthmatic subjects. Independence from DI was achieved by 
prohibiting DI for approximately four minutes prior to measurement of the partial 
flow. Volume independence was ensured by measuring Vp at the same absolute lung 
volume at each stage of challenge, in this case 35% baseline VC. The assumption that 
Vp35 is measured at isovolume relies on the assumption that TLC remains unchanged 
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during induced bronchoconstriction. The data of Kirby et al (101) and Lougheed et al 
(102) support the validity of this assumption as both studies showed no change in 
TLC with methacholine induced airway narrowing. 
Using partial flow I found a highly significant difference between the asthmatic and 
control responses to methacholine challenge, implying that even in the absence of DI, 
asthmatics are more responsive to methacholine than controls. This leads us to the. 
conclusion that hyperresponsiveness in asthma cannot be attributed entirely to an 
abnormal response to DI. This conclusion would appear to contradict the results of 
Skloot et al (9) who, using a different protocol, found that in the absence of DI 
asthmatic and control responses were similar. There are however, two essential 
methodological differences between this study and that of Skloot et al. 
I used isovolume flow as the main index of bronchoconstriction, whereas they derived 
an index in the time domain. 
Skloot et al prohibited deep breaths for the entire duration of the challenge. The 
protocol in this study allowed DI during the challenge, although partial manoeuvres 
were preceded by a four-minute DI-free period. 
Let us consider each of these in turn: 
1. The `i' index: 
Skloot et al (9) derived an index of bronchoconstriction from partial forced expiratory 
manoeuvres. Since the lung volume (EILV) at which forced expiration is initiated 
varies, they defined an index in the time domain, i, which equals the forced expiratory 
time between 25% and 75% of the partial expiration divided by the natural log of 3. 
They showed that the response to methacholine as measured by ti was similar in 
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asthmatic and control subjects and concluded that asthmatic hyperresponsiveness was 
attributable to a lack of smooth muscle relaxation with deep inspiration. The volume 
independence of the index relies on the assumption that the volume-time relation 
during forced expiration approximates to a monoexponential function. Under this 
assumption Skloot et al argue that the ti index is `equal to the reciprocal of the mean 
slope of the flow volume curve between 25% and 75% of the forced expiration' (9). 
In fact the assumption implies that the descending limb of the flow volume curve is 
rectilinear and that c is equal to the reciprocal of the gradient of the entire slope of the 
flow volume curve. Whilst this is a reasonable assumption in healthy young subjects, 
with airway narrowing the flow volume curve is characteristically concave and 
therefore the volume time curve is not monoexponential. The more severe the airway 
narrowing, the further the deviation from this assumed curve. This implies that ti is 
not independent of volume, rather it will decrease if tidal breathing occurs over a 
higher volume range. For a given degree of bronchoconstriction therefore, an increase 
in EILV (or RV) will result in a lower value of ti suggesting less bionchoconstriction. 
The rise in EILV as bronchoconstriction progresses therefore tends to mask the 
change in T. As the rise in EILV was greater in the asthmatic subjects than in the 
healthy subjects (mean 15% vs 2.4% of baseline FVC respectively), the masking 
effect would be greater in that group. The net effect would therefore be to 
underestimate the difference in responsiveness between the two groups. When 
assessed in a typical asthmatic subject, a 15% rise in EILV reduced the observed 
increase in c over the course of challenge by 54%. A change in EILV in healthy 
subjects has less effect on 'r because, as described above, the volume time relation of 
forced expiratory flow more closely approximates to a monoexponential, FET25_75and 
t are therefore less volume dependent. When assessed in a typical healthy subject a 
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2.4% increase in EILV at the end point of challenge was found to have no measurable 
effect on ti. (For a more detailed account of the mathematical arguments discussed 
here see appendix 2. ) 
I found a clear difference in the response as measured by Vp35 between the two 
groups. When r was applied to the same partial expiratory manoeuvres, I found, as did 
Skloot et at (9), a difference in responsiveness, which was not statistically significant. 
This suggests that the absence of a significant difference in r in both studies may be 
due to an inherent flaw in the index, rather than a true absence of difference. 
In the current study the responses of the two groups were compared after a cumulative 
methacholine dose of 50µg, at which point the mean fractional changes in ti in 
asthmatic and healthy subjects were 1.77 and 0.84 respectively (a difference which 
did not achieve statistical significance, p=0.075). At the point of comparison in the 
study by Skloot et al (9) the mean fractional changes in r in both asthmatic and 
healthy subjects were considerably less at 0.263 and 0.245 respectively. I have 
therefore also compared the responses of the two subject groups in the current study 
after a dose of methacholine which in the healthy subjects produced a similar mean 
change in ti to that seen in the Skloot study. After 3.125µg of methacholine the mean 
fractional changes in ti in asthmatic and healthy subjects were 0.34 and 0.25 
respectively (p = 0.62), ie as in the study by Skloot et al, at this stage of challenge the 
asthmatic and healthy responses are indistinct. 
I would argue therefore, that the apparent difference between the results of the two 
studies (the current demonstrating a distinction between asthmatic and healthy 
responses while the Skloot study did not) is due to a difference in the index of airway 
function used rather than a difference in either subject selection or challenge protocol. 
91 
2. Duration of the DI free period. 
It was my experience that prohibition of DI for the entire duration of the challenge 
was impracticable. Even if DI can be consciously resisted for prolonged periods the 
cough frequently provoked by methacholine effectively ends the DI-free period. 
In addition to the practical difficulties I had reservations as to whether the prohibition 
of DI for such an extended period was actually desirable. The available evidence on 
the duration of the effect of DI (5,25,26) suggests that this is brief. Using SGaw, Lim 
et al (5) attempted to quantify the duration of the effect of DI separately in two 
groups, one who showed bronchodilatation, the other bronchoconstriction after DI. 
The group showing bronchodilatation had a quicker recovery from the effect of DI 
than did the group demonstrating bronchoconstriction. Even with the slower recovery 
of the second group there was effectively complete restoration of baseline calibre well 
within a four-minute period. Pellegrino et al (26) also using SGaw, found almost 
complete restoration of baseline calibre 10 seconds and 60 seconds after DI in 
controls and asthmatics respectively. Green and Mead (25) measuring partial flow at 
various time intervals after deep inspiration in healthy subjects found most of the 
bronchodilating effect of DI had worn off after only 5 seconds. One study (28) 
demonstrated a measurable bronchodilating effect of DI on forced expiratory flow 
beyond four minutes (up to 6 minutes). This however was the apparent effect of a DI 
associated with an FEV 1 manoeuvre performed before the administration of 
methacholine, its effect being measured after the administration of methacholine. This 
effect was demonstrated in healthy subjects only. There is no evidence that this small 
residual bronchoprotective effect, so long after DI, would be different in asthmatic 
and healthy subjects. Whilst it is theoretically possible that in this study a difference 
in the response (asthma vs. healthy) to the preceding DI may just have been 
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measurable at 4 minutes, most of the literature would seem to suggest it is either 
absent or negligible so late after the event. It would seem unlikely to account for the 
magnitude of the difference (asthma vs. healthy) in response to methacholine 
observed in this study. 
The short term bronchodilating effect of DI is probably related to (though perhaps not 
entirely accounted for by) stretching of smooth muscle, as an enhanced 
bronchodilating effect to DI is seen in the presence of smooth muscle constrictors (1, 
5,6,8) and a diminished bronchodilating effect of DI in the presence of beta 2 
agonists (6,16,23). On the other hand prolonged inhibition of DI, particularly in the 
context of induced bronchoconstriction, may have other effects, in particular 
widespread micro-atelectasis. This in itself could affect expiratory flow. If we wish 
to study the effect of DI on smooth muscle tone such potentially confounding effects 
are better avoided. 
On the basis of the evidence available I would suggest that the four minute DI free 
period used in this study is sufficient to identify the short term effects of DI, whilst 
not being so long as to induce unwanted effects, unrelated to smooth muscle 
stretching, on expiratory flow. 
In summary, less difference in the responsiveness of asthmatic and control subjects to 
methacholine when DI is prohibited is implicit in the results of earlier studies. At 
issue is whether in the absence of DI, the asthmatic and control responses to 
methacholine are actually the same. My results suggest that the responses remain 
different even if DI is avoided, thus refuting the hypothesis that asthmatic 
hyperresponsiveness can be accounted for entirely by an altered response to DI. These 
results differ from those of Skloot et al. (9) and I suggest that the main reason for this 
difference is that the T index does not allow valid comparison between asthmatic and 
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control responses when the volume time relation during forced expiration does not 
conform to a mono-exponential and the relative volume ranges of tidal breathing 
differ. 
I conclude therefore that airway hyperresponsiveness in asthma cannot be accounted 
for solely by an abnormal response to deep inspiration. 
94 
Chapter 6 
Prediction of the Ultimate Outcome to Methacholine Challenge (A plateau 
response or apparent unlimited narrowing) using Early Changes in Small 
Airway Function. 
INTRODUCTION 
In 1984 Woolcock at el (33) described the shape of the dose response curve to 
bronchial challenge in asthmatic and healthy subjects. Bronchial challenge (with 
Histamine) was continued until a 60% fall in FEV1 occurred. Perhaps the most 
important finding in the Woolcock study was that the normal and 2 mildly asthmatic 
subjects demonstrated a plateau response. I. e. in these subjects a point was reached 
beyond which no further airway narrowing occurred despite increased doses of 
Histamine. The other subjects demonstrated a 60% fall in FEV1 in response to 
challenge (at which point the challenge was terminated) apparently demonstrating the 
capacity for unlimited narrowing. It could be argued that the presence or absence of 
this capacity for apparent unlimited narrowing is a more important facet of response 
than PD20(FEV1). It would appear to have significant implications in acute severe 
asthma and the potential for fatality. Its potential clinical usefulness is considerable. 
The practical difficulties in its measurement however, probably preclude its use as an 
everyday clinical tool. 
Assuming that, in the absence of significant bronchoconstriction, FEV1 is determined 
principally by the larger airways I reasoned that early in challenge changes in FEV 1 
probably reflect changes in calibre of the larger airways. Given their cartilaginous 
support however, narrowing of the central airways will be limited and their behaviour 
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will not determine the capacity for unlimited narrowing. Therefore, early changes in 
FEV1 may not predict ultimate outcome. Unlimited narrowing is more likely a 
function of the smaller airways. To test this hypothesis the predictive power of the 
response of a number of indices of small airway function, early in challenge was 
examined, including the index PD20(Vm20), the dose causing a 20% fall in the 
maximal flow at 20% (remaining) VC early in challenge. 
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METHOD 
I studied 13 mildly asthmatic and 11 normal subjects (Tables 3.1,3.2 and 6.1). 
Methacholine challenge was performed as described in chapter 3 (3.6 Methacholine 
Challenge - dosimeter method) to a maximum of 6,400 µg (asthmatics) or 51,200 µg 
(controls). Challenge continued until either: a 40% decrement in FEVI was recorded 
or the dose sequence completed or a maximal (plateau) response recorded. A plateau 
response was defined as a fall in FEV 1 of <5% over three successive doses. 
Flow measurements at Vm and Vp at various volume points, on the maximal and 
partial curves respectively, were derived at the same absolute lung volumes at each 
stage of challenge. As the volume at which subjects commenced their partial 
expiration inevitably varied, There was no lung volume (expressed as percentage 
baseline VC) at which Vp could be measured in all subjects at all stages of challenge. 
The greatest lung volume which afforded us the capacity to measure the provoking 
dose required to produce a 20% fall in the partial flow (PD20(Vp) ) in a majority of 
subjects was 35% baseline VC. Thus Vp35 was measured and PD20(Vp35) 
calculated. Response to challenge was also measured in terms of the provoking dose 
required to produce a fall of 20% in: FEV1, Vm20, and Vm35 and a 10% fall in 
Vm20; PD20(FEV1), PD20(Vm20), PD20(Vm35), and PDIO(Vm20) respectively 
subjects were also categorised in terms of those who demonstrated a 40% fall in 




All subjects underwent methacholine challenge (dose range 3.125µg to a maximum of 
6,400 µg). Non-asthmatic subjects who did not demonstrate either a 40% fall or a 
maximal (plateau) response with this regimen returned for a second methacholine 
challenge on day 2. 
p (three weeks later) 
Subjects returning underwent methacholine challenge with a dose range 25 µg to a 
maximum of 51,200 µg. Challenge continued until one of the following occurred: (1) 
The dose sequence was complete (2) A 40% fall in FEV 1 occurred (3) The response 
curve developed a plateau (< 5% fall in FEV 1 over final 3 doses) or (4) further doses 
were limited by systemic side effects of methacholine (Excessive sweating, salivation, 
pre-syncope or headache). 
Those limited by systemic side effects after receiving doses in excess of 25,600µg 
without having demonstrated a 40 % fall in FEV1 were deemed not to have the 
capacity for unlimited narrowing. 
In subjects who underwent the higher dose sequence challenge (day 2) responses to 
this challenge protocol are used in the analysis. 
Anal Lis 
All `provoking dose' indices derived from the methacholine challenge were 
logarithmically transformed before inter group comparisons were performed. All 
comparisons between the two groups were made using a non-paired t test. 
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RESULTS 
11 subjects (10 asthmatic, 1 control) demonstrated a 40% fall in FEV1 (group 1, `40% 
fall'). 9 control subjects demonstrated either a plateau response or less than a 40% fall 
in FEV1 at high dose (25,600µg or greater) methacholine (group 2, `plateau'). (Table 
6.1). One control and three asthmatic subjects failed to demonstrate either a 40% fall 
in FEV 1 or a clear plateau at the maximum dose of 6,400µg in the case of the 
asthmatics and after withdrawing because of systemic side effects after 12,800µg in 
the case of the control subject, these 4 subjects were not included in the analysis. 
In the case of PD20(Vm35) two subjects who plateaued in response to challenge (in 
terms of FEV1) did not achieve a 20% fall in Vm35. For the purposes of statistical 
comparison their respective PD20 (Vm35) is recorded as the maximum dose given in 
each case (1,600µg and 51,200µg). This will tend to underestimate the difference in 
PD20 (Vm35) between the two groups. 
In the case of PD20(Vp35) the flow on the `partial' expiration at 35% baseline vital 
capacity (Vp35) was only available at sufficient number of stages of challenge to 
allow determination of PD20 (Vp35) in 16 (9 asthmatics, 7 controls) of the 20 subjects. 
The lung volume at which the partial flow was commenced appeared almost random, 
though the theoretical systematic bias in only comparing partial flow in subjects who 
had a measurable partial flow at 35% VC would be to the selection of a more severe 
asthmatic group. This bias per se would not appear to undermine the finding of an 
absence of a statistically significant difference between the two groups in the PD20 
(Vp35) index. However the reduced number of subjects available for comparison 
using this index does make a type 2 statistical error more likely. 
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Although values for baseline lung function (FEVI/FVC) were different between the 
two groups (p=0.04) there was considerable overlap between the two groups (fig 6.1). 
Baseline lung function could therefore not be used to predict the ultimate outcome of 
challenge with any degree of precision. In the subjects who failed to demonstrate a 
40% fall in FEV1 none demonstrated a 20% fall either therefore in no subject in group 
2 could a PD20(FEV 1) be determined. By definition all subjects in group 1 had a 
PD20(FEV1), with median 77.5 µg. Clearly there were no overlapping values of this 
index between the two groups. 
Log PDlo(Vm20) and Log PD20(Vp35) were highly significantly different between the 
two groups (p = 0.0001 and 0.0007 respectively). Though in each case the ranges of 
values demonstrated some overlap (Table 6.1 and figs 6.2 & 6.3). 
Log PD20(Vm20) and Log PD20(Vm35) were also highly significantly different 
between the two groups (p < 0.000001). In neither case did any of the values ranges 
overlap between the two groups (Table 6.1 and figs 6.4 & 6.5, ). 
The percentage change in FEV 1 at the dose after which a 20% fall in Vm20 had been 
achieved was calculated for each subject. The mean value of this index was not 
different between the two groups (p = 0.61), (fig 6.6). 
In subjects where a plateau, in terms of Vm35 and Vp35, could be established the 
maximum fall (mean of final 3 values) from baseline were: mean(sd)% 19.8(6.8)% 
and 63.5(11.2)% respectively. 
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Table 6.1 
Group 1 ('40% fall') N Group 2 ('plateau') N `p' value 
FEV1/FVC 0.77(0.07)(0.65-0.86) 11 0.83(0.04)(0.78-0.88) 9 0.04 
PD20(FEV 1) 166(230)(10.2-722.7) 11 No subject achieved a 20% 
reduction in FEV 1 
0 
Log PD20(FEV1) 1.89(0.58) 11 0 
PD10(Vm20) 6.89(10.6)(0.6-35.6) 11 3814(6810)(2.6-18920) 9 
Log PD10(Vm20) 0.49(0.55) 11 2.54(1.24) 9 0.0001 
PD20(Vm20) 13.6(16.9)(1.1-48.4) 11 5398(7862)(94.5-23040) 9 
Log PD20(Vm20) 0.79(0.59) 11 3.15(0.86) 9 <0.000001 
PD20(Vm35) 25.6(37.2)(1.5-127.1) 11 9435(16243)(181-51200) 7* 
Log PD20(Vm35) 1.05(0.59) 11 3.46(0.77) 7* <0.000001 
PD20(Vp35) 4.6(6.0)(1.1-19.8) 10 195(282)(5.6-688) 6 
Log PD20(Vp35) 0.43(0.43) 10 1.75(0.81) 6 0.0007 
FEV1 as % baseline 
after PD20(Vm220) 
94.3(4.0)(88.5-102.1) 11 93.4(3.7)(85.2-97.4) 9 0.61 
For log data: mean(standard deviation) 
For non-log data: mean(standard deviation )(range) 
N: the number in each group contributing to the stated mean 
*2 subjects in group 2 had not achieved a 20% fall in Vm35 by the end of challenge. 
Thus only 7 subjects contribute to the calculated mean. The difference in the means 
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The presence of a maximal (plateau) response or the converse, the capacity for 
unlimited airway narrowing is a less familiar facet of the response to bronchial 
challenge than PD20(FEV 1) but potentially far more important. The obvious clinical 
correlate would appear to be the susceptibility to very severe, potentially fatal, 
exacerbations of asthma. The phenomenon described by Woolcock (33) is now well 
established with most healthy subjects and some mild asthmatics demonstrating a 
plateau response. The proportion of subjects demonstrating the phenomenon has 
varied between studies. Much of this variability will be due to subject selection but of 
course the value to which FEV1 is allowed to fall before the presence or absence of a 
plateau response is determined will have a significant bearing on it. Intuitively it 
seems likely that the maximal fall in FEV1 at plateau will vary, with some being 
below the 40% or even 60% threshold. Those who do not plateau prior to the given 
`safety' threshold in a particular study probably fall into two categories: Those in 
whom a plateau would be established at a lower value of FEV1 and those who have 
the capacity for true unlimited narrowing. In an absolute sense therefore it could be 
argued that any study may be mis-positioning the dividing line in this dichotomy, 
however in a practical sense those who do plateau below such threshold (particularly 
60%) are probably more appropriately categorised with those most susceptible to fatal 
exacerbations of asthma. 
Some work has been done to try and understand the `protective mechanism' that 
healthy and some asthmatic subjects seem to possess which limits airway narrowing. 
Sterk et al (35) found that limited maximal airway narrowing to methacholine in 
nonasthmatics is not due to a change in adrenergic, cholinergic, or ganglion- 
109 
transmitted-nonadrenergic inhibitory activity nor to the release of prostaglandins. A 
study by De Jongste et al (36) which compared maximal bronchoconstriction in vivo 
and airway smooth muscle responses in vitro found no significant correlation. 
Suggesting that maximal bronchoconstriction in vivo is not limited by the maximal 
contractility of airway smooth muscle. This was consistent with the findings of Sterk 
et al (37) who found the response to combined histamine and methacholine was not 
significantly larger than the maximal response to histamine alone, suggesting that the 
plateau is due to factors other than limited smooth muscle activation. 
I considered whether the plateau of the dose-response to methacholine, could be 
explained by the airway dilation that follows deep inspiration (DI) in non-asthmatics, 
a bronchoprotective factor known to differ between asthmatic and healthy subjects. In 
common with a previous study by Sterk et al (49) in the subjects in whom plateaus 
could be established I found the maximum fall in Vp35 to be greater than the 
maximum fall in Vm35. This, of course, confirms previously reported data on the 
greater bronchodilating effect of deep inspiration in the context of induced 
bronchoconstriction. It is clear therefore that DI had offered some degree of 
bronchoprotection in these subjects. The response to DI is therefore clearly an 
important factor at least in terms of limiting the maximal plateau response. However 
the existence of a plateau in a partial flow response to challenge implies that a 
`mechanism' limiting airway narrowing in response to challenge would appear to be 
operating independent of the effects of deep inspiration. 
In an animal model Mink et al (109) demonstrated that the maximum expiratory flow 
at a low lung volume (50% FVC) was a sensitive index of small airway narrowing. 
On this premise, the studies which compare the degree of maximal narrowing at 
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different lung volumes (38,41) would seem to suggest that the capacity for unlimited 
narrowing, where it exists, lies within the small airways. 
An in vitro study by Mitchell et al (42) reported changes in response to acetylcholine 
(ACh) with concurrent measurement of smooth muscle shortening, lumen narrowing 
and flow in large and small porcine bronchi. Maximum muscle shortening and lumen 
narrowing was greater in small than large bronchi. Small airways were 250-times 
more sensitive to ACh than large airways, for all measurements. But perhaps most 
interestingly high doses of ACh stopped flow in small bronchi, but produced a plateau 
in large bronchi, the cartilaginous support of the large airways perhaps protecting 
them from unlimited narrowing, even in the context of maximal smooth muscle 
stimulation. 
Whatever the underlying mechanism and whatever the site within the airways the 
presence or absence of the capacity for unlimited narrowing is clearly important with 
potentially important clinical ramifications. To challenge subjects to a maximal 60% 
or even 40% maximal fall in FEV 1 would not seem to be an appropriate investigation 
for routine clinical practice. 
Even the complex mathematical modelling used by Aerts et al (40) failed accurately 
predict to the plateau even when many of the data points from the challenge were fed 
into the model. It would seem that the early changes in FEV 1 may not actually 
contain the information required to estimate ultimate outcome of challenge. 
I reasoned that if the small airways were indeed the site where the capacity for 
unlimited narrowing resided then early changes of small airway function during 
challenge may predict the ultimate outcome. If so this would provide further support 
for small airways as the site of this facet of response and may suggest a possible 
practicable clinical test of the presence of the capacity for unlimited narrowing. 
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By chance the subjects in this study who demonstrated a plateau all had maximal falls 
in FEV 1 of less than 20% thus in no subject from this group could a PD20(FEV 1) be 
established. There is no absolute reason why this should be so, maximal responses 
could lie between 20% and 40%. The fact that in this group no subjects were in that 
range implies a clear separation between the two groups in the study. The `predictive 
power' of the indices under investigation therefore may be somewhat overestimated 
and some caution should be exercised when interpreting the results. 
The results in this study show that baseline lung function in the form of FEV 1/FVC 
has no predictive power for ultimate outcome to challenge. 
In this study PD20(FEV 1) has 100% sensitivity and specificity for predicting the 
ultimate outcome of challenge. That is to say subjects in whom a PD20(FEV1) could 
be established i. e. demonstrated a 20% fall in FEV1 all failed to demonstrate a plateau 
in response. However in the study doses of up to 51,200µg were delivered before the 
failure to establish a PD20(FEV1) was confirmed in all subjects. Thus in this study at 
least the presence or absence of a 20% fall in FEV 1 did not provide an `early 
warning' of the presence or absence of a plateau. PD20(Vm20) and PD20(Vm35) were 
also 100% sensitive and specific. Interestingly though these indices, PD20(Vm20) in 
particular, were established at a much earlier stage of challenge than PD20(FEV1). In 
fact the percent change in FEV 1 at the dose after which PD20(Vm20) was established 
(ie a 20% fall in Vm20 had occurred) was small and not different between the two 
groups. Albeit in a post hoc analysis we see that after just 5 doses of methacholine 
(cumulative dose 50mcg) the ultimate outcome to challenge was entirely predictable 
in all subjects from the change in Vm20 at that point. To use FEV 1 in this way would 
have required a minimum of 9 doses (cumulative dose 800mcg). 
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One important caveat needs to be added at this point. In order to properly assess the 
response to challenge in terms of `partial' flows - without the distorting effect of deep 
inspiration, the measurement of the `partial' flow was performed first at each stage of 
challenge and the total number of deep breaths at each stage was limited to one (to 
allow measurement of FEVI and `maximal' flows). One limitation of this protocol 
therefore is the absence of averaging and the associated increase in `noise' in the 
measurement of each index at each stage of challenge. This did not appear to have any 
significant bearing on the determination of PD20(FEV1) in that there was no obvious 
random distortion of the response curve. However in the assessment of PD20(Vm20) 
in 3 subjects (1 asthmatic, 2 controls) once the entire dose response curve was 
observed it was apparent the `outlying' results could have led to a falsely low 
assessment of this index had it been used exclusively to determine end point of 
challenge. For example in subject la (fig 6.7) observation of the whole dose response 
curve suggests a PD20(Vm20) between 25µg and 50µg. However had the challenge 
been performed with the sole purpose of determining PD20(Vm20) and the occurrence 
of the first value for Vm20 below 80% of the baseline been taken as the end point of 
the challenge then a very different value for PD20(Vm20) would have been 
determined. 
By definition PDIO(Vm20) is established even earlier in challenge than PD20(Vm20). 
However what is gained in speed may be lost in precision. As can be seen in fig 6.2, 
the ranges of values for the two groups showed considerable overlap implying a 
weaker predictive power. 
Interestingly PD20(Vp35), like PDIo(Vm20) although highly significantly different 
between the two groups, shows overlap in its value ranges and thus demonstrates a 
weaker predictive power. This may be due to the variability in response to deep 
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inspiration. The `ultimate outcome' in challenge is usually determined by the change 
in a DI dependant value, FEV 1, perhaps it is therefore best predicted by another DI 
dependent index, Vm35 say. Vp35 is one step further removed from FEV 1 by, the 
response to DI, which has the effect of adding `noise' (a variable factor) to the index. 
In summary all the `within challenge' indices have considerable predictive power for 
the ultimate outcome of challenge. Indices relying on very small changes in a value 
such as PDIO(Vm20) or those based on a flow independent of a DI may suffer from 
excess `noise' which in turn weakens their predictive power. PD20(FEV1), 
PD20(Vm35) and PD20(Vm20) in this study all predict outcome with 100% sensitivity 
and specificity. The indices of small airway function are however predictive at a much 
earlier stage of challenge. These data are supportive of the argument that the presence 
or absence of unlimited airway narrowing lies in the function of the small airways. It 
clearly suggests that the behaviour of these airways early in challenge reflect 
behaviour of FEV1 late in challenge. To establish a practicable test for `early 
detection' of the ultimate outcome of challenge however requires further work. What 
the indices of small airway function gain in sensitivity they may lose in specificity, 
they are generally more volatile, less reproducible than FEV1. The presence of 
`outlying' results in the case of PD20(Vm20) as discussed above is perhaps a 
manifestation of this, though it should be remembered that because of the limitations 
of this protocol only one measurement of each value was performed at each stage of 
challenge. In a clinical context at least 3 measurements even of FEV 1 would be 
performed at each stage of challenge with reproducibility being monitored. It seems 
likely that under such conditions PD20(Vm20) for example would be more 
reproducible. Also in a practical sense the sensitivity of the index may compensate for 
a degree of volatility. For example PD20(Vm20) varied by a factor of 44 within the 
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group that demonstrated apparent unlimited narrowing yet the mean values of the 2 
groups differed by a factor of 397. Thus, in this group at least, the volatility of the 
index did not significantly hinder its predictive power. Of course this study did not 
provide us with any data on within subject reproducibility. Further studies may 
conclude that an `optimum' index such as PD20(Vm35) or even PD20(Vm50) offers 




The relationships between small airway mechanical function, the concentration 
of exhaled nitric oxide, the response to bronchial challenge and the response to 
deep inspiration. 
INTRODUCTION 
Exhaled nitric oxide (NO) is an index of airway inflammation in asthma. In various 
studies it has been shown to correlate with indices of asthma severity such as 
eosinophils in induced sputum and airway responsiveness. Most studies however 
report no correlation between NO and FEV1. The reason for this is not clear. It may 
be that the indices reflect different aspects of the disease process (one cellular 
function, one mechanical function), which are not necessarily closely correlated. 
Alternatively the two indices may be reflecting changes in different parts of the 
bronchial tree. FEV1 is an index largely dependent on the function of larger airways, 
whereas the principal site of production of the NO measured in exhaled breath is the 
terminal airways (74,81). In chapter 61 discussed the importance of the function of 
the small airways in determining the response to challenge and the relatively poor 
correlation between that response and baseline FEV 1. This may go some way towards 
explaining the said disparity. I. e. exhaled NO may be reflecting inflammation (and 
thus function) principally in the small airways, this in turn would be expected to 
correlate with the response to bronchial challenge yet may be more loosely related to 
indices such as FEV 1 which in the absence of significant airway obstruction is 
probably determined principally by the function of the more central airways. 
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In chapter 61 discussed the importance of another facet of responsiveness, the 
presence or absence of a maximal (plateau) response. The function of the small 
airways is particularly important in determining this. In the study reported in chapter 6 
changes in the function of small airways, very early in bronchial challenge, as 
measured by PD20(Vm20) were 100% sensitive and specific for the presence of a 
plateau response. I therefore examined the relationship between exhaled NO and 
PC20(Vm20), as a surrogate index for the ultimate response to challenge (plateau or 
unlimited narrowing). In chapter 6 the relationship examined was between changes in 
small airway function within challenge and the ultimate outcome. Baseline indices 
such as FEV (% predicted) were found not to correlate with the ultimate outcome. 
Focusing more specifically on smaller airway function at baseline and using Vm50 
and Vm20 as indices of this, in this study I also looked directly at the relationship of 
Pre challenge Vm50 & Vm20 with PC20(Vm20). I wished to know whether the 
function of the smaller airways at baseline (prior to the delivery of the first dose of 
methacholine) correlated with the ultimate outcome of challenge even though FEV 1 
(% predicted) may not. 
My aim was to examine the relationships between: Pre challenge exhaled NO, 
baseline indices of smaller airway function (Vm50 & Vm20) and methacholine 
responsiveness (in terms of the standard index PC20(FEV 1) and PC20(Vm20) as a 
surrogate marker of `ultimate' outcome). The relationship of each of these indices to 
baseline FEV 1 would also be considered. 
The study reported in chapter 5 and the paper by Skloot et al (9) together establish the 
fact that although an abnormal response to DI in asthmatic subjects cannot in isolation 
explain asthmatic hyper-responsiveness to bronchial challenge it is a contributory 
factor. Similarly the study reported in chapter 6 together with previously published 
117 
studies (10,41,49)demonstrates that although an absolute limitation to narrowing in 
response to bronchial challenge is not entirely determined by the response to DI it 
does have a protective effect. The bronchodilating effect of DI will reduce the extent 
of (maximal) narrowing. In some subjects this may limit airway narrowing to a safer, 
non-fatal degree. Thus the relationship of the response to DI to both these facets of the 
response to bronchial challenge is complex. I therefore examined the relationship of 
that response, as measured by both M/P and SGaw ratio (which appear to be 
determined by different mechanisms (chapter 4) to both indices of the response to 
bronchial challenge PC20(FEV 1) and PC20(Vm20), exhaled NO, baseline FEV1, 
Vm50 and Vm20. 
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METHOD 
I studied 15 steroid naive asthmatic and 10 normal subjects (tables 3.1,3.2 and 7.1). 
Normal subjects were all hospital employees. They reported no symptoms of asthma, 
had never received a diagnosis of asthma from a physician and had normal 
spirometric volumes. All subjects were non-smokers and had had no recent upper 
respiratory tract infection. Approval was obtained from the local Ethics Committee 
and written informed consent was obtained. The various indices of respiratory 
function were derived according to the following protocols. 
Methacholine Challenge (tidal breathing method), exhaled NO, spirometric values, 
SGaw, SGaw ratio (pre and post DI) and maximal / partial (M/P) ratio were all 
derived by the methods described in chapter 3. The tidal breathing method for 
methacholine challenge was used as this method allowed a greater DI free period prior 
to the measurement of partial flows than the dosimeter method. The maximum 
expiratory flow at 50% and 20% vital capacity (Vm50 & Vm20) were derived from 
the same manoeuvres as FEV1. Because of the inter-individual variability in EILV the 
greatest lung volume at which an M/P ratio could be derived varied between subjects. 
The highest volume common to all subjects was 30% VC (70% VC expired). Three 
technically good manoeuvres were obtained in each subject. The mean M/P ratio at 
30% VC was calculated. 
Protocol 
After an initial screening visit subjects returned at a later date and performed the 
respiratory function tests in the following order: 
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1. M/P ratio followed by a 15 minute rest period. 2. SGaw ratio. 3. Exhaled NO. 4. 
MCh challenge, preceded by baseline spirometry from which FEV1, Vm50 and Vm20 
were derived. 
After methacholine challenge subjects were given an inhaled short acting beta-2 
agonist if needed. They were monitored until lung function had returned to 95% of pre 
challenge values and they were feeling well. 
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RESULTS 
There was no significant difference in the mean values of FEV 1 (%predicted), NO, 
M/P or SGaw ratio between the two groups. 
Pre challenge Vm20 displayed no significant correlation with any index of airway 
function or exhaled NO. The correlation between pre challenge Vm50 and exhaled 
NO did not reach significance in a two tailed t test (Table 7.2). Across all subjects pre 
challenge Vm50 demonstrated a significant correlation with PC20(Vm20) (Fig 7.1), 
though failed to reach significance in either subgroup alone (Table 7.3). In asthmatic 
subjects (Table 7.4) there was a statically significant correlation between the 
concentration of exhaled NO and each index of the response to challenge, the same 
correlations were also significant across all subjects (control and asthmatic). The 
strength of the relationship and its statistical significance was greater in the case of 
LogPC20(Vm20) (Fig 7.2) than LogPC20 (FEV1). There were no significant 
relationship between NO and FEV1(% predicted) either in the asthmatic (Fig 7.3) or 
control subjects nor across all subjects (Table 7.5). In both asthmatic and control 
subjects the response to DI, as measured by either M/P or SGaw ratio, showed no 
statistically significant correlation with any index of airway function, or with the 









FEV1 (% pred) 98.7 (10.7) 10 91.9(13.41) 15 0.19 
FEV1/FVC 0.84(0.05) 10 0.77(0.08) 15 0.02 
SGaw 0.146(0.039) 10 0.110(0.042) 15 0.04 
Log PC20 (FEV1) -0.26(0.94) 12 
Log PC20 (Vm20) 0.209(0.453) 7 - 0.95(0.81) 15 0.002 
Vm50 273.5(88.1) 10 209.7(45.0) 15 0.025 
NO 6.48(4.62) 10 15.7 (18.7) 15 0.14 
M/P 0.98(0.23) 10 1.05(0.26) 15 0.55 
SGaw ratio 1.06(0.17) 10 1.00(0.13) 15 0.36 
All values stated as mean(SD) 
p value from 2 tailed Student's T test 
N: number of subjects in the respective group. 
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Table 7.2 




Asthma Control All subject Asthma Control All subject 
-0.44 -0.07 -0.3 -0.3 -0.0 -0.3 
p 0.10 0.8 0.9 0.1 0.8 0.1 
N 1 1 2 1 10 2 
`p' =2 tailed Significance, `r' = Pearson Correlation's co-efficient. 





'p' =2 tailed Significance, 'r' = Pearson Correlation's co-efficient. 
Asthma Control Asthma Control all subjects 
0.32 n/ 0.43 0.6 0.54 
0.31 0.11 0.12 0.009 
N 12 1 22 
0.2 0.19 0.7 0.2 
0.3 0.4 0.0 0.1 
N 12 1 2 
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Table 7.4 








-. 69 -. 68 
p . 004 . 08 
N '1 7 
`p' =2 tailed Significance, 
`r' = Pearson's Correlation co-efficient. 
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Table 7.5 
Correlations: FEV 1 (% predicted) vs Pre challenge Vm50, Responses to Challenge 
and Exhaled Nitric Oxide 







0.7 . 15 . 20 -. 
18 
0.001 . 621 . 474 . 51 
N 1 12 1 1 
0.8 . 49 -. 37 
0.00 . 25 . 284 
N 1 1 
'p' =2 tailed Significance, 'r' = Pearson's Correlation co-efficient. 
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Table 7.6 
Correlations: Response to DI vs FEV1(% predicted), Pre challenge Vm50, Responses 
to Challenge and Exhaled Nitric Oxide 
Asthma 
M/F 
FEVI LogPC20(FEV) LogPC20(Vm20) 





-. 12 -0.3 . 03 . 12 . 113 
. 65 0.2 . 90 . 648 . 68 
N 1 1 12 1 1 
-. 05 -0.3 . 313 . 171 -. 043 
. 84 0.1 . 322 . 541 . 87 
N 1 1 12 1 1 
. 10 -0.1 . 118 -. 48 
. 76 0.62 . 801 . 152 
N 1 10 7 1 
-. 42 -0.4 -. 211 -. 02 
. 22 0.2 . 65 . 95 
N 1 10 1 
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10.0 20.0 30.0 40.0 50.0 60.0 70.0 
129 
DISCUSSION 
The absence of statistically significant differences in the mean values of FEV 1 
(%predicted), NO, M/P and SGaw ratio between the two groups reflects the fact that 
the asthmatic group were very mild in severity. This is perhaps an inevitable 
consequence of recruiting steroid naive asthmatics in the UK in the current day. As 
this study was not designed to explore differences between asthmatic and healthy 
subjects the lack of a more clear distinction between the two groups was not seen as 
prohibitive. However, as discussed below, a broader spectrum of severity may have 
identified relationships between the indices discussed here that have otherwise 
remained unclear. 
Nitric oxide (NO) plays an important role as an inflammatory mediator in the airways. 
Exhaled nitric oxide is known to be elevated in asthma (73-78) and its role as a 
marker of severity has been extensively investigated in a variety of clinical settings. 
The relationships reported to various clinico-pathological indices of asthma however 
have been somewhat variable. Many studies, in a variety of clinical contexts, have 
identified a correlation between exhaled NO and bronchial hyper-responsiveness, 
including: steroid naive asthma (76,78) and asthma associated with seasonal allergic 
rhinitis (74) as well as chronic stable asthma (79). In the context of steroid naive 
asthma it has also been shown to correlate with diurnal variability in peak expiratory 
flow (PEF) (76). Although NO was found to correlate with FEV 1(% predicted) in a 
large group across a broad spectrum of severity ranging from subjects attending the 
emergency department with acute severe asthma through chronic stable asthma to 
non-asthmatic controls (75), it is usually reported as not correlating significantly with 
FEV 1(% predicted) (76-78,80) other functional markers of severity such as symptom 
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scores (76) or beta-agonist use (76). The reason for this disparity between the 
correlation of NO with bronchial responsiveness (PD20(FEV1)) and the absence of 
correlation with FEV 1 is not clear. 
In chapter 61 discussed the importance of the function of the small airways in 
determining the `ultimate' outcome of bronchial challenge (plateau or unlimited 
narrowing) and the relatively poor correlation between this facet of response and 
baseline FEV1. Although the PD20(FEV 1) and the ultimate outcome are different 
facets of the response to challenge, in chapter 61 established that a close correlation 
exists between the two. A relationship may therefore exist between the baseline 
function of the small airways and PD20(FEV1). If so and if as reported exhaled NO is 
principally derived from the terminal airways (74,81) then this may go some way 
towards explaining the said disparity. I. e. exhaled NO may be reflecting inflammation 
(and thus function) principally of the small airways, this in turn would be expected to 
correlate with the response to bronchial challenge (chapter 6) yet may be only loosely 
related to indices such as FEV 1 which in the absence of significant airway obstruction 
is probably determined principally by the function of the more central airways. 
The findings in this study were broadly consistent with this hypothesis. In asthmatic 
subjects and across all subjects although the correlation between pre challenge Vm50 
(an index more dependent on small airway function than FEV1) and exhaled NO did 
not reach significance in a two-tailed t test. A one tailed test is significant and given 
published data on the relationship between exhaled NO and airway function may have 
been more appropriate. Notwithstanding this, the current study has to be read as 
inconclusive on the issue of a relationship between pre challenge Vm50 and exhaled 
NO. This may well be due to a flaw in the design of the study. Vm50 pre challenge, 
as with Vm20, was derived from a single expiration. Random variability could have 
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been reduced had a mean of three manoeuvres been used. This same error may also 
have been responsible for the lack of correlation seen between baseline Vm20, an 
index even more prone to random variability than Vm50, and either the response to 
challenge or exhaled NO. 
Across all subjects although the correlation between baseline Vm50 and log 
PC20(FEV 1) did not reach statistical significance, the correlation between baseline 
Vm50 and log PC20(Vm20) (which in chapter 6 was shown to predict the ultimate 
outcome of challenge with a very high degree of sensitivity and specificity) was 
statistically significant. Further and to close the loop, the correlation between exhaled 
NO and response to challenge was statistically significant as has been previously 
reported. This was the case using either index of response: log PC20(FEV 1) or 
1ogPC2o(Vm20). Interestingly the strength of the correlation and its statistical 
significance was greater with 1ogPC20(Vm20) than 1ogPC20(FEV 1). 
Consistent with the findings in chapter 6, previously published data and the proposed 
linking mechanism in this chapter baseline FEV 1(% predicted) demonstrated no 
correlation with exhaled NO, logPC20(Vm20) or logPC20(FEV1). Log transformation 
of NO did not qualitatively alter the statistical significance of any of these 
correlations. The correlation between baseline Vm50 and FEV 1(% predicted) is not 
surprising. It may have been more appropriate to have tested the hypothesis using an 
index more dependent on small airway function and less dependent on central airway 
function than Vm50, such as Vm20 (appropriately averaged) or Closing Volume, a 
measurement reported to be an index of terminal airway function. 
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The response to DI 
We know too from the study in chapter 6 and other published data (10,41,49) that 
within challenge the response to DI is an important determinant of the level at which a 
maximal response occurs. In some cases as discussed above that could make the 
difference to an individual subject demonstrating a plateau or the apparent capacity 
for unlimited narrowing. Would the response to DI at baseline therefore have any 
predictive power as to the outcome of challenge? Lim et al (11) reported on a positive 
relationship between the magnitude of the increase in residual volume following deep 
breaths (0 RV) at baseline and the degree of fall in FVC following histamine 
inhalation (0 FVC) though this was at a dose of histamine inducing only a 20% fall in 
FEV1, not the maximal, plateau response. 
In chapter 41 introduced a hypothesis (to be tested in chapter 8) that the abnormal 
asthmatic response to DI is due to fluid flux. This would be more specifically 
dependent on the degree of acute inflammation / oedema than the overall increase in 
thickness of the airway wall. The overall thickness is due to the combined effects of 
oedema and chronic re-modelling. Although these two factors are distinct one might 
expect some correlation between the two. The more `severe' the asthma the greater 
the inflammation, the inflammatory process over time being ultimately responsible for 
the re-modelling. As explained in the model by James et al (64) the increased 
thickness of the airway wall can explain most, if not all, of the observed reduction in 
FEV 1 and PC20(FEV 1) etc. in asthma. Thus one might, in a large cross-sectional 
study, find a correlation between the response to DI (related to the degree of oedema) 
and the FEV1 (related to total wall thickness). Such a correlation is reported by Lim et 
al (5). However, the relationship between the increase in airway wall thickness due to 
re-modelling and that due to oedema will not always be the same. The severity of the 
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inflammatory process at a particular point in time may determine the degree of airway 
wall oedema but factors such as the duration of the inflammatory process and the 
previous use of steroids (113) for example will also influence the degree of re- 
modelling. Certainly when the greater part of the airway wall thickening is due to 
acute inflammation and oedema, during an acute exacerbation for example, one might 
expect to find a good correlation between the response to DI and FEV 1. Such a 
correlation was observed in a longitudinal study by Lim et al (16) when M/P and 
FEV1 were monitored in subjects recovering from an acute exacerbation of asthma. 
However in circumstances when the greater part of the airway wall thickness is not 
due to acute inflammation one might expect the correlation between the response to 
DI and FEV 1, to be less strong. 
The asthmatic subjects in this study were steroid naive and therefore, for the reasons 
described above, may have had a disproportionate amount of re-modelling for the 
severity of asthma observed at the time of the study. They were also a fairly 
homogeneous group. The absence of a statistically significant correlation between the 
response to DI (by either index, M/P or SGaw ratio) and the indices of airway 
function: PC20(FEV1), PC20(Vm20), baseline FEV1 and VmSO or even NO may 
therefore be explained by the likely weakness of the correlation between the degree 
of acute inflammation and the degree of re-modelling. 
In summary the findings in this study (in conjunction with those in chapter 6) may 
explain the disparity in previously reported studies of the presence of a correlation 
between exhaled NO and the response to bronchial challenge and the general absence 
of a correlation between exhaled NO and the standard indices of baseline airway 
function such as FEV1. Exhaled NO would appear to be reflecting function of the 
small airways which are crucial in determining the response to bronchial challenge, 
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particularly the `ultimate' outcome. On the other hand, in the absence of significant 
airway obstruction, FEV 1 is, more dependent on the function of the larger airways. 
The absence of a correlation between the response to DI and any other index of 
airway function in this steroid naive, relatively homogeneous asthmatic group is 
consistent with the hypothesis that the bronchoconstrictor response to DI is dependent 
on the degree of acute inflammation/oedema only, whilst many of the other indices of 
airway function depend on the overall thickness of the airway wall. 
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Chapter 8 
A Novel Hypothesis to Explain the Bronchoconstrictor Effect of Deep Inspiration 
in Asthma 
INTRODUCTION 
The bronchodilatation post DI in healthy subjects is generally attributed to a reduction 
in airway smooth muscle tone but the mechanism underlying the bronchoconstriction 
observed post DI in many asthmatics is not fully established. 
In the inflamed asthmatic airway wall, fluid flux across leaky capillaries between the 
intra and extra vascular compartments in response to changes in hydrostatic pressure 
is likely to be greater than in a healthy, non-inflamed airway. I therefore hypothesised 
that the large, negative intra thoracic pressure generated during a rapid deep 
inspiration would cause extravasation of fluid into the asthmatic airway wall, 
increasing its thickness and reducing the lumen, while in the healthy airway without 
inflammatory changes such an effect would be absent or insignificant. 
I have tested this hypothesis by comparing the bronchoconstricting effect of DI in 
asthmatic and healthy subjects when inspiration was performed both with and without 
added resistance. Inspiration against added resistance was used to enhance the 
negative intra thoracic pressure during DI. My hypothesis predicted that asthmatic 
subjects would show increased airway narrowing following DI against resistance as 
compared with resistance free inspiration and that this difference would be greater 
than that seen in healthy subjects. 
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METHOD 
I studied 10 mildly asthmatic and 11 normal subjects (tables 3.1,3.2 and 8.1). SGaw 
was measured by the method described in chapter 3. Additional resistance for 
inspiration was provided by the attachment, in series, to a standard mouthpiece of an 
orifice 3mm wide and 3.4cm long. 
Preliminary Studies 
A pilot study was conducted in 10 subjects to confirm the practicability of this degree 
of resistance and the time to inspire a full breath through it. In each subject I measured 
the time (t) to perform a forced maximal inspiration from residual volume (RV) to 
total lung capacity (TLC) through resistance and the inspiratory vital capacity (NC) 
during unencumbered breathing. This study demonstrated that 't' was, to a very good 
approximation, a linear function of IVC: t=2.12 x IVC - 0.05 (R2 = 97%, P< 
0.0005). Inspiratory times varied between 5 and 14 seconds. 
In a second pilot study the magnitude of the intra thoracic pressure generated during 
the two manoeuvres was assessed in four subjects after swallowing an oesophageal 
balloon. The subjects performed the two inspiratory manoeuvres that were to be 
performed in the main study. I found that maximum (negative) pleural pressure during 
forced inspiration against resistance was achieved early in inspiration and was 
sustained for most of the duration of the inspiration. During the controlled, resistance 
free, inspiration the negative pressure generated gradually increased throughout 
inspiration, achieving its maximal (negative) value at the end of inspiration. The peak 
(negative) pressure generated during forced inspiration against resistance was 
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significantly greater than the peak (negative) pressure during controlled, resistance 
free, inspiration (mean, - 62.9cmH2O vs. - 23.1 cmH2O, p=0.019). 
Protocol 
The full study was performed at a later date. A series of respiratory manoeuvres was 
performed in the following sequence: 
1. Inspiratory Vital Capacity (IVC). 
Following 2 or 3 tidal breaths subjects exhaled to RV and then performed a non 
forced inspiration to TLC. The best of three technically good manoeuvres was 
recorded and used to predict the inspiratory time 't' through resistance using the 
previously derived equation: t=2.12 x IVC - 0.05. 
Subjects then rested for five minutes. 
2. Specific Airway Conductance (SGaw) 'pre DI'. 
The'pre DI' manoeuvre began with tidal breathing for one minute. The volume time 
trace was monitored on screen to ensure that no deep breaths occurred. After a one- 
minute DI free period, SGaw, TLC, FRC and RV were measured. The sequence was 
repeated at least twice more after at least 1 minute of tidal breathing on each occasion. 
The mean of three technically good measurements was calculated and recorded as the 
'pre DI' SGaw. 
3. SGaw'post DI without resistance' (SGawDI) 
Using the same apparatus, after 2 or 3 tidal breaths, subjects performed a non-forced 
expiration to RV. From RV they inspired slowly (at a steady rate) to TLC. The 
inspiratory rate was such that the entire inspiration took 't' seconds. This precise 
timing was achieved by practice and an audible second count '1,2,..., t' during 
inspiration. The actual time taken was measured to ensure parity with the time 't' 
138 
predicted for the inspiration performed against resistance. From TLC subjects 
performed a swift but non-forced expiration to RV. The manoeuvre was repeated 
twice more and following the third timed inspiration to TLC subjects returned to FRC. 
Panting at FRC as before allowed calculation of SGaw. The mean of three technically 
good measurements was calculated and recorded as the'SGawDI . 
4. SGaw'post DI against resistance' (SGawDI RES) 
Using the same apparatus, subjects began by performing 2 or 3 tidal breaths without 
added resistance. They then performed a non-forced expiration to RV, followed by 
inspiration with maximum effort through resistance to TLC. Subjects were required to 
achieve a full inspiration as quickly as possible. The time taken was noted to ensure 
the accuracy of the predicted time 't' and thus matching with the time of the earlier 
controlled, resistance free, inspiration. From TLC subjects performed a swift but non- 
forced expiration to RV against no resistance. The manoeuvre was repeated twice 
more. Following the third maximal inspiration to TLC subjects returned to FRC. 
Panting at FRC as before allowed calculation of SGaw. The mean of three technically 
good measurements was calculated and recorded as the 'SGawDI RES . 
Analysis 
In order to assess the effect of the negative intrathoracic pressure generated by forced 
inspiration against resistance I compared SGawDI RES with 
SGawDI in each subject 
group. The % change SGawDI to SGawDIRES in each subject was calculated. 
Comparison was made of this % change between the 2 groups. FRCDI RES' the lung 
volume at which SGawDI RES was measured, and FRCDI, the 
lung volume at which 
SGawDI was measured, were also compared within each group. 
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The time taken to inspire when inspiration was performed at a voluntarily controlled 
rate without additional resistance (t DI) was compared with the calculated time to 
inspire with maximal force performed against added resistance (t DI RES ). 
Within group results were compared using a paired t test and between group 
comparisons were made using a non paired t test. 
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RESULTS 
All results are expressed as mean (standard deviation). Subject groups were of similar 
mean age and sex distribution (Table 8.1). The asthmatic subjects had mild airways 
obstruction. 
In asthmatic subjects, SGaw following forced inspiration against resistance (SGawDI 
REs) was on average 13.5% less than SGaw measured following the voluntarily 
controlled deep inspiration against no added resistance (SGawDI) (Table 8.2). This 
difference was statistically significant (p = 0.003). In healthy subjects there was no 
difference in the SGaw following the two types of inspiratory manoeuvre. The 
change, SGawDI to SGawDI REs was significantly different between the two groups. 
In the asthmatic subjects there was no statistically significant difference between 
FRCDI and FRCDI RES although 
in healthy subjects a difference of similar average 
magnitude was statistically significant. 
There were no differences in the inspiratory time when measured at the voluntarily 
controlled rate without added resistance {mean(SD): asthma 9.48(2.26) and normals 
10.49(3.15)} and the calculated time to inspire with maximal force performed against 





Age 32.8 (5.1) 30.2 (5.0) 
FEV1 (% predicted) 90.8 (27.8) 97.5 (10.5) 
FEV1/FVC 0.72 (0.14) 0.80 (0.07) 
SGaw (pre DI) 0.094 (0.037) 0.154 (0.048) 
Sex 5M 6M 




SGawDI 0.084 (0.036) 0.141 (0.041) 
SGawDI RES 0.071 
(0.031) 0.138 (0.039) 
% change -13.5 (11.0)* - 0.5 (12.4)* 
p 0.003 0.67 
FRC DI 4.29 
(1.36) 3.69 (1.19) 
FRC 
DI RES 4.07 (0.93) 3.49 (1.12) 
p 0.23 0.02 
mean (standard deviation) 
SGaw measured in cmH20'i. sec'1 
* comparison of % change in the asthmatic vs. healthy group. p=0.02 
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DISCUSSION 
The different responses of asthmatic and healthy airways to deep inspiration probably 
reflect a fundamental feature of asthmatic pathophysiology. Studies in healthy 
subjects consistently show a bronchodilating response to DI (7-10,14,18,22) but in 
asthma the response is more variable (4-6,11,15,16). While milder asthmatics 
simply display a more limited bronchodilator response, subjects with more severe 
asthma show bronchoconstriction post DI. Indeed some studies have identified an 
inverse relationship between the bronchodilating effect of DI and severity (5,16,17, 
20). The bronchodilatation post DI in healthy subjects is largely attributable to a 
reduction in airway smooth muscle tone. This explanation is consistent with the 
enhanced bronchodilating effect of DI seen in the context of methacholine induced 
bronchoconstriction in both asthmatic (4-6) and healthy subjects (1,8) and with 
diminution of the bronchodilating effect of DI following administration of ß2 
sympathetic agonists (6,16,23). 
The mechanism underlying the bronchoconstriction observed post DI in some 
asthmatics is not fully established. A diminution of the bronchodilating effect of DI 
can be explained by a reduction in the degree of stretch imposed on smooth muscle by 
DI in asthmatic subjects (24). An additional mechanism however is required to 
explain the observed bronchoconstrictor response. Hysteresis within the parenchyma 
resulting in lower lung recoil pressure post DI and a diminished retractile force on the 
airway wall has been proposed as such a mechanism with the net effect on airways 
post DI being a balance of the hysteresis within the airways and parenchyma - the 
'relative hysteresis hypothesis' (4,7,14,23,29). This mechanism explains many 
reported findings but it does not account for the observations in a study by Burns (4) 
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and the study reported in chapter 4 in asthmatic subjects of an increase in isovolumic 
forced expiratory flow post DI occurring in conjunction with a reduction in SGaw. 
I therefore propose the following mechanism, which, together with the stretching 
effect of DI on airway smooth muscle, would account for all the published 
observations: 
A large proportion of the increased thickness of the airway wall in asthma is due to 
inflammation, which includes: increased vascularity, increased mucosal blood flow 
(114), leaky capillaries, inflammatory exudate and oedema (115). Even in stable 
situations the equilibrium of intra /extra vascular fluid flux is dynamic and delicately 
balanced. This equilibrium is likely to be altered by the markedly negative intra 
thoracic pressure generated during a rapid deep inspiration. Such pressure applied to a 
leaky, low-pressure capillary bed across the capillary wall would cause extravasation 
of fluid into the airway wall, increasing its thickness and reducing its lumen (and thus 
reducing SGaw). The increased interstitial fluid would also render the airway wall 
more turgid, reducing its compliance as recently reported with airway wall 
inflammation in vitro (110,1.11). Consequently the airway would be less susceptible 
to compressive forces during the subsequent forced expiration. Given the dependence 
of fluid flux on hydrostatic as well as oncotic pressure the argument that fluid flux 
would occur in response to a change in pressure is perhaps not controversial. A more 
debatable point is whether sufficient fluid would have moved from the intra- to extra- 
vascular space given the pressure changes and time frame involved to account for the 
changes in airway conductance observed. No direct measurements have been made 
however it is worthy of note that the intra-thoracic pressures generated by the two 
manoeuvres in this study were around -63cmH20 in the case of the inspiration against 
resistance and only -23cmH2O during resistance free inspiration. This compares with 
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a typical intra-capillary pressure in the bronchial circulation of around 28cmH20 
(116). The duration of the application of these pressures was between 5 and 14 
seconds. It has also been shown that relatively small changes in airway wall oedema 
can potentiate the bronchoconstricting effect of smooth muscle constriction (64,69) 
and lead to significant airway narrowing. In an animal study Uhlig et al (72) 
demonstrated a significantly enhanced response to methacholine, after airway wall 
vascular engorgement compared with before: 67.8% vs 10.8% increase in Raw. Yet 
the morphometric data suggested that the engorgement process had produced only 
small changes in airway wall cross sectional area: 3.2 mm2 versus 2.8 mm2 in airways 
with a mean size >3mm, for example. 
Thus relatively small net movements of fluid could be responsible for the observed 
changes. In healthy subjects, without inflammatory changes, such a mechanism would 
be absent or insignificant. 
The hypothesis is consistent with studies reporting an inverse relationship between the 
bronchodilating effect of DI and severity of asthma (and thus oedema) (5,16,17,20). 
One animal study (117) appeared to contradict these earlier findings. CT imaging in 
anesthetized sheep demonstrated that lung inflation produced greater 
bronchodilatation following prior bronchoconstriction by increased airway wall 
oedema (bradykinin) than following bronchoconstriction induced by smooth muscle 
constriction (methacholine). The fundamental difference however is that in this study 
`deep inspiration' was achieved by positive pressure ventilation. This is entirely 
consistent with the proposed hypothesis which would predict in this context that `deep 
inspiration' would invoke not only bronchodilatation secondary to smooth muscle 
stretch but also a reduction in airway wall oedema secondary the intra-thoracic 
positive pressure (as opposed to negative intra-thoracic pressure normally associated 
146 
with a deep inspiration). In a second animal study by one of the same authors, in the 
same journal, in the same year (118) induced airway wall oedema was found not to be 
associated with enhanced responses to methacholine. The study, I believe, suffers 
from the same `flaw'. The interaction between smooth muscle shortening, airway wall 
oedema and lumenal narrowing was again observed in the context of positive pressure 
ventilation. 
In the current study I have tested the proposed hypothesis by comparing the 
bronchoconstricting effect of DI (reduction in SGaw) in asthmatic and healthy 
subjects inspiring both with and without added resistance. In the design of the study 
the order of the two manoeuvres was not randomised. This introduces a theoretical 
risk of carry over (order bias) however it was felt that the pause between manoeuvres 
as the equipment was prepared and the intrinsic duration of the second manoeuvre 
(SGawDI xis) with its three forced deep inspirations would minimise any residual 
effect from the previous slow DIs in the SGaWDI manoeuvre. The inspiratory 
manoeuvres were designed to be identical in their time-volume relationship in order to 
minimise differences in the behaviour of smooth muscle or any other element in 
which intrinsic tone varies in response to stretch, including factors contributing to 
both airway and parenchymal hysteresis. Inspiration against added resistance 
enhanced the negative intra thoracic pressure during DI. Thus the only difference 
between the two types of inspiratory manoeuvre was the change in intra thoracic 
pressure. The fluid flux hypothesis predicts enhanced airway narrowing in asthmatic 
subjects following DI against resistance as compared with resistance free inspiration. 
In healthy subjects without airway inflammation the hypothesis predicts substantially 
less sensitivity to changes in intra thoracic pressure and less difference in SGaw 
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following the two types of inspiratory manoeuvre. These results are entirely consistent 
with this hypothesis. 
In conclusion this study suggests that the changes in airway function observed post DI 
in asthmatic subjects result not only from changes in airway and parenchymal 
components of the lung which are subject to the stretch/relaxation phenomenon 
(already extensively studied) but also from the effects of transient changes in intra- 
thoracic pressure on the inflamed asthmatic airway wall. 
Further testing is required to investigate the full implications of this mechanism. The 
potential to influence airway wall oedema by manipulation of the intra-thoracic 
pressure could have clinical benefits. Positive pressure applied by non-invasive 
ventilation, for example, could have the effect of reducing airway wall oedema. If 





Defining the response to DI 
Part of the purpose of this thesis has been to explore and hopefully better understand 
the physiological mechanisms that underpin the responses to a deep inspiration, both 
in healthy controls and asthmatics. Whilst there appeared to be some common 
consensus that asthmatic subjects gained less bronchodilatation than healthy subjects, 
with some even displaying frank bronchoconstriction after DI, the published studies 
actually reported a much more mixed and complex picture. To attempt to explore the 
mechanisms underpinning the responses to DI our first task therefore had to be to 
define precisely what those responses were, in both asthmatic and healthy subjects. 
In the study reported in chapter 4 M/P ratio was found to vary in a systematic way 
with the volume at which it was measured, increasing as lung volume decreases both 
in asthmatic and healthy subjects. Several possible explanations for this finding are 
discussed in the chapter, the most plausible explanation however would appear to be 
that the dependence on lung volume reflects a differing effect of DI on different 
generations of airway, with the larger airways showing relatively less 
bronchodilatation, perhaps due to a lesser stretching affect on the smooth muscle 
during DI. 
The study in chapter 4 also found that the response to DI as measured by forced 
expiration appeared to contradict the response as measured by SGaw. The finding is 
consistent with another study reported in the literature (4). In the relatively mild group 
of asthmatics studied SGaw ratio suggested bronchoconstriction post DI, yet mean 
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M/P ratio, at the same lung volume, suggested bronchodilatation. The healthy subjects 
showed the converse pattern, with SGaw ratio suggesting bronchodilatation and M/P 
ratio suggesting bronchoconstriction. On the basis of these findings four criteria were 
identified that must be satisfied by any mechanism (operational in conjunction with 
smooth muscle stretch/relaxation) explaining the abnormal asthmatic response to DI: 
(i) It must account for bronchoconstriction post DI in asthmatics. 
(ii) It must account for an increase in airway wall rigidity post DI in asthmatics. 
(iii) It should be distinct from, and thus vary independently of, smooth muscle 
stretch/relaxation. 
(iv) It should be absent or insignificant in healthy subjects. 
Within the relative hysteresis hypothesis (4,7,14,23,29), greater hysteresis of the 
parenchyma than the airways in asthma could account for bronchoconstriction post DI 
(SGaw<1). However parenchymal hysteresis results in lower lung recoil pressure post 
DI and would lessen the retractile force on the airway wall. This would render the 
airway more, rather than less, susceptible to compressive forces during forced 
expiration, thus condition (ii) is not satisfied. 
The following novel mechanism is proposed: 
That the negative intra thoracic pressure generated during a rapid deep inspiration 
could cause a net extravasation of fluid into the airway wall, increasing its thickness 
and reducing its lumen (thus reducing SGaw and tending to reduce forced expiration). 
The increased interstitial fluid would also render the airway wall more turgid and less 
susceptible to compressive forces during the subsequent forced expiration, tending to 
enhance forced expiration. The net effect of this newly proposed mechanism on 
forced expiration being a balance of these two opposing effects. This novel hypothesis 
was subsequently tested, the results are reported in chapter 8. The overall effect of DI 
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however would remain a net balance between the effects of this newly proposed 
mechanism and effects on smooth muscle. 
The previously well described DI associated reduction in smooth muscle tone due to 
stretching is likely to occur in both healthy and asthmatic subjects, although there is 
evidence that this effect may be diminished in asthma. The dilating effect of a 
reduction in muscle tone on airway calibre is clear. A reduction in smooth muscle 
tone however may also reduce airway wall rigidity. Thus, although SGaw would be 
increased, the effect on forced expiratory flow would be determined by the relative 
magnitude of these two opposing effects. 
The response of maximal flow and SGaw to DI in any individual asthmatic is 
therefore the net result of the effects of the reduction of smooth muscle tone and fluid 
flux in the airway wall. In healthy subjects, in the absence of inflammation in the 
airway wall, the degree of fluid flux would be significantly diminished, perhaps 
negligible and the response to DI would be determined largely by the reduction in 
smooth muscle tone. 
Testing the Novel Hypothesis 
In chapter 8 the fluid flux hypothesis was tested by comparing the 
bronchoconstricting effect of DI (reduction in SGaw) in asthmatic and healthy 
subjects inspiring both with and without added resistance. Inspiration against added 
resistance enhanced the negative intra thoracic pressure during DI but the inspiratory 
manoeuvres were designed to be identical in their time-volume relationship in order to 
minimise differences in the behaviour of smooth muscle or any other element in 
which intrinsic tone varies in response to stretch, including factors contributing to 
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both airway and parenchymal hysteresis. Thus the only difference between the two 
types of inspiratory manoeuvre was the change in intra thoracic pressure. The fluid 
flux hypothesis predicts enhanced airway narrowing in asthmatic subjects following 
DI against resistance as compared with resistance free inspiration. In healthy subjects 
without airway inflammation the hypothesis predicts substantially less sensitivity to 
changes in intra thoracic pressure and less difference in SGaw following the two types 
of inspiratory manoeuvre. Our results are entirely consistent with this hypothesis. 
In conclusion this study suggests that the changes in airway function observed post DI 
in asthmatic subjects result not only from changes in airway and parenchymal 
components of the lung which are subject to the stretch/relaxation phenomenon 
(already extensively studied) but also from the effects of transient changes in intra- 
thoracic pressure on the inflamed asthmatic airway wall. 
A word on Cellular biomechanics 
There has been some recent focus on the importance of periodic stretch and relaxation 
inherent in tidal breathing for normal functioning of airway smooth muscle (27,54, 
57,119,120). Shen et al (119) reported the response to methacholine in rabbits 
ventilated at varying frequency and with varying magnitudes of tidal volume, 
including `zero volume' ("static conditions"). The increase in Raw with challenge was 
significantly greater under static conditions than during tidal ventilation at any 
frequency or volume. Increases in the volume or frequency of tidal ventilation 
resulted in significant decreases in Raw in response to methacholine. They concluded 
that the effect of lung volume changes on airway responsiveness in vivo is primarily 
related to the stretch of airway smooth muscle. Though interestingly, given the 
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positive pressure associated with ventilation, these findings could also be explained 
by the oedema hypothesis discussed in chapter 8. 
An important in vitro study was reported by Fredberg et al (57) in which isolated, 
maximally contracted bovine tracheal smooth muscle was subjected to tidal stretches. 
When the amplitude of imposed tidal stretch was very small, the steady-state value of 
the active force approximated the isometric force, the muscle was stiff and displayed 
little hysteresis in the tidal cycle. When the amplitude of imposed tidal stretch was 
increased the active force and stiffness decreased and greater hysteresis was 
demonstrated. The muscle could be maintained in these steady, dynamically 
determined contractile states for as long as the tidal stretches were sustained. 
It is thus argued that the reduced mechanical load on airway smooth muscle in 
asthma, due to the unlinking of airway and parenchyma (55,56) would lead to 
diminished smooth muscle stretch in during normal tidal breathing and therefore a 
more `latched' state (between actin and myosin) with increased active force and 
stiffness of the muscle. Whether this possible `semi-permanent' contracted state has 
additional functional relevance to the diminution in asthma of the transient relaxation 
in tone following a deep inspiration or whether it is simply another manifestation of 
the same phenomenon is not clear. Also, the same group that first described the 
biomechanical effect on smooth muscle of periodic tidal stretches (57) in a later paper 
(120) quantified the stretch amplitude required to cause active force or muscle 
stiffness to fall by half, or hysteresivity to double, as slightly greater than 2%. By 
contrast, the authors report the stretch amplitude expected during quiet breathing at 
rest is 4%. The difference in stretch amplitude between smooth muscle in an 
asthmatic and healthy airway during tidal breathing would be difficult to quantify 
though intuitively would seem unlikely to differ by as much as a factor of 2. The 
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functional significance of this observed in vitro phenomenon in explaining the 
abnormal response of asthmatic airways therefore remains unclear. At most, the 
phenomenon may account for a diminution in the bronchodilating effect of DI in 
asthma. It would not appear to account for the bronchoconstriction observed in many 
subjects. 
Whether functionally important or not, these apparent changes in smooth muscle 
behavior are not a primary facet of the asthmatic state but secondary to geometrical 
changes in the airway wall. 
The Relationship between the response to DI and bronchial hyperresponsiveness 
The possible relationship between the generally diminished bronchoprotective effect 
of DI in asthmatic subjects and the increased responsiveness to non-specific bronchial 
stimuli is intriguing. The response to bronchial stimuli is usually measured in terms of 
the change from baseline of FEV 1, which by definition is preceded by a deep 
inspiration. It would seem obvious therefore that the abnormal response to DI must at 
least play a part in the observed hyperresponsiveness to bronchial challenge in 
asthma. This idea was first mooted by Fish in 1981 (13). In fact Fish's hypothesis was 
that: `Asthmatic hyperresponsiveness is due to a problem of smooth muscle 
relaxation with deep inspiration'. The hypothesis was later tested by Skloot (9) who 
concluded that it was correct. 
First a careful dissection of the hypothesis is required. 
As discussed above and in chapter 4, whilst a failure of smooth muscle to relax post 
DI may account for a diminished bronchodilator effect in asthmatic subjects, it cannot 
account for frank bronchoconstriction. A` problem of smooth muscle relaxation' 
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cannot therefore be the only difference between the asthmatic and healthy responses 
to DI. Thus the diminished bronchoprotective effect of DI in asthmatic subjects, even 
within the context of bronchial challenge is unlikely to be exclusively due to a 
problem of smooth muscle relaxation. At face value therefore, without further 
exploration, the hypothesis would appear to be false. However, although not stated as 
such, the more general hypothesis that: `Asthmatic hyperresponsiveness is due to an 
abnormal response to DI' is actually what Skloot tested. 
This, more limited, hypothesis would certainly seem worthy of testing. In doing so 
further careful cautious and rigorous interpretation of results is likely to be required. 
We know from numerous other studies (7,8,10,17-20) including the study which 
lead to the development of the hypothesis (13) that there is a diminished 
bronchoprotective effect of DI in asthmatic subjects, the fact therefore that this 
abnormal response is pi of the explanation for asthmatic hyperresponsiveness is not 
controversial, in fact it could be considered to be already established. Thus to prove 
the (more limited) hypothesis any study would have to demonstrate that without the 
benefit of DI the bronchial responsiveness of healthy subjects is not just closer to that 
of asthmatic subjects but is in fact the same. 
Skloot (9) tested this hypothesis and declared it to be true. This was widely reported at 
the time, which included extensive coverage in the lay press, as a `big breakthrough' 
in our understanding of asthma. The study is however fatally flawed. As discussed in 
chapter 5, the `T' index used the measure the response to challenge will systematically 
underestimate the difference in the responsiveness between the asthmatic and control 
subjects. The absence therefore of a statistically significant difference in the 
responsiveness between the two groups in this study cannot be used to conclude that 
the responses are in reality the same. 
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I retested the hypothesis using an index not prone to the same error. I found a highly 
significant difference between the asthmatic and control responses to methacholine 
challenge, implying that even in the absence of DI, asthmatics are more responsive to 
methacholine than controls. This leads us to the conclusion that hyperresponsiveness 
in asthma cannot be attributed entirely to an abnormal response to DI. A detailed 
comparison of my methodology and that used by Skloot is described in chapter 5. 
The Response to DI and the Maximal Response to Bronchial Challenge 
The presence of a maximal (plateau) response or the converse, the capacity for 
unlimited airway narrowing is a less familiar facet of the response to bronchial 
challenge than PD20(FEV 1) but potentially more important. The obvious clinical 
correlate would appear to be the susceptibility to very severe, potentially fatal, 
exacerbations of asthma. The phenomenon described by Woolcock (33) is now well 
established with most healthy subjects and some mild asthmatics demonstrating a 
plateau response. The proportion of subjects demonstrating the phenomenon has 
varied between studies. Much of this variability will be due to subject selection but of 
course the value to which FEV1 is allowed to fall before the presence or absence of a 
plateau response is determined will have a significant bearing on it. Intuitively it 
seems likely that the maximal fall in FEV 1 at plateau will vary, with some being 
below a 40% or even 60% threshold. Those who do not plateau prior to the given 
`safety' threshold in a particular study probably fall into two categories: Those in 
whom a plateau would be established at a lower value of FEV 1 and those who have 
the capacity for true unlimited narrowing. In an absolute sense therefore it could be 
argued that any study may be mis-positioning the dividing line in this dichotomy, 
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however in a practical sense those who do plateau below such threshold (particularly 
60%) are probably more appropriately categorised with those most susceptible to fatal 
exacerbations of asthma. 
I considered whether the plateau of the dose-response to methacholine, could be 
explained by the airway dilation that follows deep inspiration (DI) in non-asthmatics. 
In common with a previous study by Sterk (49) in subjects in whom a plateau could 
be established the maximum fall in Vp35 was found to be greater than the maximum 
fall in Vm35. It is clear therefore that DI had offered some degree of 
bronchoprotection in these subjects. Indeed in this and similar studies it my well be 
that a large bronchodilating response to DI could cause a plateau to occur above rather 
than below whatever safety threshold is set (in this case 40%) thus re-classifying the 
subject. The response to DI is therefore clearly an important factor, at least in terms of 
limiting the level of maximal plateau response. However the very existence of a 
plateau in a partial flow response to challenge implies that a `mechanism' limiting 
airway narrowing in response to challenge would appear to be operating 
independently of the effects of deep inspiration. 
Small Airways and the Maximal Response to Bronchial Challenge 
Given their cartilaginous support I reasoned that narrowing of the central airways 
during bronchial challenge will be limited and the presence or absence of apparent 
unlimited narrowing to challenge is more likely dependant on function of the smaller 
airways. Assuming too that, in the absence of significant bronchoconstriction, FEV 1 
is determined principally by the larger airways I further reasoned that early in 
challenge changes in FEV 1 probably reflect changes in calibre of the larger airways 
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and may not therefore reflect the ultimate outcome to challenge. I reasoned that if the 
small airway were indeed the site where the capacity for unlimited narrowing resided 
then early changes of small airway function within challenge may predict the ultimate 
outcome. 
In the study reported in chapter 6 although PD20(FEV1) was 100% sensitive and 
specific for predicting the ultimate outcome of challenge, PD20(Vm20) and 
PD20(Vm35) were also 100% sensitive and specific and predicted outcome at a much 
earlier stage of challenge. In fact the percent change in FEV1 at the dose after which 
PD20(Vm20) was established (ie a 20% fall in Vm20 had occurred) was small and not 
different between the two groups. 
Indices relying on very small changes in a value such as PDIO(Vm20) or those based 
on a flow independent of a DI such as PD20(Vp35) although highly significantly 
different between the two groups, showed overlap in their value ranges and thus 
demonstrated a weaker predictive power. PD20(FEV1), PD20(Vm35) and PD20(Vm20) 
in this study all predicted outcome with 100% sensitivity and specificity. The indices 
of small airway function are however predictive at a much earlier stage of challenge. 
The findings in this study are consistent with the hypothesis that the presence or 
absence of a capacity for unlimited airway narrowing lies in the function of the small 
airways. It demonstrates that the behaviour of these airways early in challenge reflects 
behaviour of FEV 1 late in challenge. To establish a practical test for `early detection' 
of the ultimate outcome of challenge however requires further work. What the indices 
of small airway function gain in sensitivity they may loose in specificity, due to 
excess `random variability', being generally more volatile and less reproducible than 
FEV I. Though it should be noted that in this group at least, the volatility of the index 
did not significantly hinder its predictive power. This study did not provide data on 
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within subject reproducibility. Further studies should look PD20(Vm50) and 
PD30(Vm20) as well as PD20(Vm35) and PD20(Vm20). The `optimum' index should 
provide the appropriate balance between sensitivity and reproducibility. 
NO, Baseline Function of the Small Airways and the Response to Bronchial 
Challenge 
The findings in the study in chapter 6 are interesting but generate more questions than 
they answer. If it is the function of small airways that determines the ultimate 
response to challenge could an assessment of small airway function at baseline (pre 
challenge) be used to predict outcome? 
The published data on the concentration of exhaled nitric oxide (NO) is interesting 
and perhaps of some relevance, it suggests an apparent parallel. NO is known to 
correlate well with the response to challenge, at least in terms of PD20(FEV 1) (74,76, 
78,79) yet not with baseline FEV 1(76-78,80). The reason for this disparity is not 
clear. Exhaled NO is also thought to be derived from the peripheral airways (74,81). 
The question arose as to whether exhaled NO would correlate with the mechanical 
function of the small airways and whether NO as well as the mechanical function of 
the small airways would correlate with the response to challenge. 
On the issue of the relationship between Vm50 and NO the findings in the study 
reported in chapter 7 were inconclusive. The absence of a clear correlation between 
NO and an index of small airway function may have been contributed to by a number 
of design flaws in the study. An index more exclusively dependent on small airway 
function such as Closing volume or Vm20 should have been selected and an 
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appropriately averaged measurements taken. This aspect of the hypothesis requires 
further testing. 
Across all subjects although the correlation between Vm50 and log PD20(FEV1) did 
not reach statistical significance, the correlation between Vm50 and log PD20(Vm20) 
(which in chapter 6 was shown to predict the ultimate outcome of challenge with a 
very high degree of sensitivity and specificity) was statistically significant. 
Further, and to close the loop, the correlation between exhaled NO and response to 
challenge was statistically significant as has been previously reported (74,76,78,79). 
This was the case using either index of response: log PD20(FEV 1) or logPD2o(Vm20). 
Interestingly the strength of the correlation and its statistical significance was greater 
with logPD20(Vm20) than logPD20(FEV 1). 
Consistent with the findings in chapter 6, previously published data and the proposed 
linking mechanism in this chapter baseline FEV 1(% predicted) demonstrated no 
correlation with exhaled NO, logPD20(Vm20) or logPD2o(FEV1). 
In summary the findings in this study (in conjunction with those in chapter 6) go 
someway to explain the disparity in previously reported studies of the presence of a 
correlation between exhaled NO and the response to bronchial challenge and the 
general absence of a correlation between exhaled NO and the standard indices of 
baseline airway function such as FEV1. Exhaled NO may to be reflecting function of 
the small airways, which are crucial in determining the response to bronchial 
challenge, particularly the `ultimate' response. On the other hand, in the absence of 
significant airway obstruction, FEV1 is, to a greater degree, determined by the 
function of the more central airways. 
160 
The response to DI and the response to Bronchial Challenge 
We know too from the study in chapter 6 and other published data (10,41,49) that 
within challenge the response to DI is an important determinant of the level at which a 
maximal response occurs. However in chapter 7 no correlation was found between the 
response to DI at baseline and the response to challenge. 
As explained using the model by James et al (64) the increased thickness of the 
airway wall may explain most, if not all, of the reduction in FEV1 and the enhanced 
responsiveness to bronchial challenge in asthma. The overall thickness of the wall 
would be due to the combined effects of oedema and chronic re-modeling. In chapter 
41 introduced a hypothesis (tested in chapter 8) that the abnormal asthmatic response 
to DI is due to fluid flux. This would be more specifically dependant on the degree of 
acute inflammation / oedema in the airway wall rather than its overall thickness. As 
discussed, although these two factors (overall thickness and degree of oedema) are 
likely to be closely linked, the relationship will vary. For the reasons discussed in 
chapter 7 one might expect the relationship to be weaker in this steroid naive group, 
which may explain the weakness observed in the relationship between indices such as 
FEV1 & PC20(FEV 1) and the response to DI in this group. 
In summary, the absence of a correlation between the response to DI and any other 
index of airway function in this steroid naive relatively homogeneous asthmatic group 
is consistent with the hypothesis that the response to DI is dependent on the degree of 
acute inflammation/oedema only, whilst many of the other indices of airway function 
depend on the overall thickness of the airway wall. 
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Chapter 10 
Conclusions and Possible Directions for Future Research 
The Small Airways 
Given their cartilaginous support narrowing of the central airways during bronchial 
challenge will be limited and the presence or absence of the capacity for unlimited 
narrowing to challenge is more likely to be dependant on the function of the smaller 
airways. The sensitivity and specificity of changes in small airway function very early 
in bronchial challenge in predicting the ultimate outcome (limited or unlimited airway 
narrowing) supports this hypothesis. Furthermore, it suggests a potential clinically 
practical and safe test of the capacity for unlimited airway narrowing. Further studies 
however are required to determine the optimum index. 
M/P ratio is greater at lower lung volumes in both asthmatic and healthy subjects. 
This dependence of the response to DI on the lung volume at which it is measured 
suggests that the effect of DI on different generations of airway may vary - with a 
greater bronchodilating effect seen in the smaller airways. With progressive 
bronchoconstriction during challenge the small airways play an increasingly important 
role in determining the maximal expiratory flow. This in addition to the increased 
smooth muscle tone may account for the increase in M/P as bronchial challenge 
proceeds. If M/P ratio at lower lung volumes does indeed reflect the response to DI in 
smaller airways then, given the importance of the small airways in determining the 
response to challenge, this may be the more pertinent index of the DI response. This 
hypothesis requires further testing. 
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The response to a Deep Inspiration 
The study reported in chapter 5, in conjunction with the original paper by Skloot (9) 
established that in the context of bronchial challenge the diminished asthmatic 
response to DI (as compared to the healthy response to DI) plays a role in 
distinguishing the asthmatic and healthy responses to challenge. It is clear however 
from the study reported in chapter 5 that this mechanism alone is only part of the 
explanation, it cannot account fully for the abnormal asthmatic response to challenge. 
I. e. there must be a further factor or mechanism determining this fundamental feature 
of asthmatic pathophysiology. 
The study reported in chapter 6 confirms previously reported findings that the 
maximal or plateau response to challenge, where it exists, occurs following a lesser 
percentage change from baseline in indices preceded by, and therefore dependent on 
the response to, DI such as Vm20 and FEV 1 than indices independent of the effects of 
DI such as Vp20. It is clear therefore that the bronchodilating effect of DI does offer 
some protective effect in terms of the maximal response to bronchial challenge. 
However the existence of a maximal or plateau response in many subjects in DI 
independent indices such as Vp20 clearly demonstrates that whatever factor or 
mechanism ultimately limits narrowing, it operates independently of the effect of DI. 
Thus in terms of the maximal response to challenge, as with PD20(FEV 1), the 
response to DI is influential but does not explain all findings. 
In the novel hypothesis proposed in chapter 4, the bronchoconstrictor response to DI 
in asthmatic subjects is explained by fluid flux within the airway wall in response to 
changes in intra-thoracic pressure during DI. The hypothesis is tested by exaggerating 
the intra-thoracic pressures generated by the inspiratory manoeuvre and measuring the 
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functional response. Care was taken in the design of the study to exclude changes in 
other parameters that could influence outcome. In could be argued that in the absence 
of any other explanation for the results then this study constitutes `proof of the 
hypothesis. However a study, which includes more direct evidence of the 
hypothesised fluid shift, is likely to be more convincing to the wider scientific 
community. The study by Uhlig et al (72) demonstrated that very small changes in 
airway wall cross sectional area had large functional effects. The magnitude of the 
morphometric changes reported are probably beyond the resolution of current (in 
vivo) imaging techniques. I suspect therefore that an animal study with direct 
measurement of pathological specimens would be required to demonstrate the small 
volumes of fluid flux likely to be involved. 
On the premise that the hypothesis is correct, I argue that in the absence of acute 
inflammation/oedema, in non-asthmatic subjects say, the effect of this proposed 
mechanism would be diminished, perhaps negligible. It would seem probable that the 
magnitude of the effect of this mechanism, would be related to the severity and degree 
of acute inflammation within the airway wall. This in turn, although clearly related to, 
would be distinct from, the overall increase in thickness of the airway wall seen in 
asthma - comprising changes of chronic remodelling as well as the effects of acute 
inflammation/oedema. One might, nevertheless, expect some correlation between 
these two features. The more severe the asthma the greater the inflammation, and the 
greater the degree of re-modelling. As in the model by James (64) the overall 
thickness of the airway wall may explain many of the abnormal features of asthmatic 
airway function such as the reductions in FEV 1 and PD20(FEV 1). Therefore one 
might, in a large cross-sectional study, find a correlation between the response to DI 
(related to the degree of acute inflammation) and FEV 1 (related to total wall 
164 
thickness), such a correlation is reported by Lim (5). However the relationship 
between the thickening due to re-modeling and that due to oedema will not always be 
the same. Factors other than severity of the inflammatory process at the time of testing 
will determine the degree of re-modeling that is has occurred, the duration of 
inflammatory process and the previous use of steroids (113) for example. The steroid 
naive asthmatic group studied in chapter 7 may therefore have had a disproportionate 
amount of re-modelling for the degree of acute inflammation present. In such 
circumstances one might expect the correlation between the response to DI and FEV 1 
say, to be less strong. Indeed in this group M/P and SGaw ratio did not correlate with 
FEV 1 or the response to challenge. 
Alternatively in circumstances when a greater part of the airway wall thickening is 
due to acute inflammation/oedema, during an acute exacerbation for example, one 
might again expect to find a good correlation between the response to DI and FEV1. 
Such a correlation was observed in a longitudinal study by Lim et al (16) when M/P 
and FEVI were monitored in subjects recovering from an acute exacerbation of 
asthma. 
It would seem therefore that the response to DI relates to, and therefore can give us 
information on, the degree of `acute inflammation / oedema' only, not the totality of 
airway wall thickening. It is the overall increase in airway wall thickness rather than 
the changes of acute inflammation alone that would be expected to be most closely 
linked to airway lumenal narrowing and abnormalities of airway function such as the 
diminution of FEV 1 and the response to bronchial challenge. 
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C02 carbon dioxide 
DI Deep Inspiration 
e=2.7182818... 
EILV End Inspiratory Lung Volume (the lung volume at the end of 
tidal inspiration) 
FET25-75 the time expire the middle 50% of vital capacity (25% to 75% 
expired) during forced expiration. 
FEV1 Forced Expiratory Volume in one second 
FRC Functional Residual Capacity (the lung volume at the end of 
tidal expiration) 
FVC Forced Vital Capacity 
In natural logarithm (to the base e) 
IVC Inspiratory Vital Capacity 
M/P the ratio of the maximal expiratory flow rate following a 
maximum inspiration to the maximal expiratory flow rate 
following a partial expiration (Vm / Vp) at a given isovolumic 
point (chapt. 3.3) 
NO Nitric Oxide (the concentration of) 
PD20(FEV1) The provoking dose causing a 20% fall in FEV1 from baseline 
during bronchial challenge (dosimeter method, chpt 3.6) 
PD20(Vm20) The provoking dose causing a 20% fall in Vm20 from baseline 
during bronchial challenge (dosimeter method, chpt 3.6) 
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PC20(FEV1) The provoking concentration causing a 20% fall in FEV 1 from 
baseline during bronchial challenge (tidal breathing method, 
chpt 3.7) 
Ptp-V quasi-static transpulmonary pressure-volume 
RV Residual Volume 
sd Standard deviation 
SGaw Specific airway conductance 
SGaw ratio ratio of. SGaw ('post DI') performed immediately after a deep 
inspiration to SGaw ('pre DI') performed after a period of time 
in which deep inspiration was avoided. 
SGawDI Specific airway conductance performed after a slow, timed 
deep inspiration (chapter 8) 
SGawDI RES 
Specific airway conductance performed after a forced deep 
inspiration against added resistance (chapter 8) 
ti = FET25a5 / ln3 
TGV Thoracic Gas Volume, as measured by body plethysmography 
TLC Total Lung Capacity 
VC Vital Capacity 
Vm35 expiratory flow rate at 35% vital capacity (remaining) during 
forced expiration preceded by a maximal inspiration 
Vp50 expiratory flow rate at 50% vital capacity during forced 
expiration preceded by a partial inspiration 
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Appendix 2 











so FVC =2x (t75 - t25) = twice time to expire middle 50% of volume 
MMEF 
Define 
tau = FVC x 0.5 
MMEF In 3 
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t25 #75 
Skloot et al inform us that this index is the reciprocal of the mean slope of the flow 
volume curve between 25% and 75% of the forced expiration. 
This is of course not true, unless one makes a major assumption about the shape of the 
volume time curve 
The Unstated Assumption 
Skloot makes the unstated assumption that volume-time curves conforms perfectly to 
the single negative exponential: - 
v=FVC(e ) ............................................................ 1. 
-kt or e=V................................................................. 2. 
FVC 
Given this assumption, let us show that Skloot's statement about the slope on the flow 
volume curve is true... 
from 1. 
f= dv = -K (FVC) e 
kt 
............................... 3. dt 
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from 2. 
-Kt = In (V ) ......................................................... 4. 
(FVC) 
rearranging 
t=- I In (--Y-) ...................................... 5. 
K (FVC) 
let t25 = the time to expire 25% of the FVC, by which time V=0.75 FVC 
so 
t25 =-1 In 0.75 t75 =-I In 0.25 .................. 6. KK 
recall 
MMEF = 0.5 FVC = 0.5 FVC 
t75 - t25 -1/K( In 0.25 - In 0.75 ) 
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so 




tau = FVC x 0.5 
MMEF ln3 
= In 3x0.5 




Aside So what is K? 
recall 
V= FVC (e 
kt ) 
from 2. & 3. 
f= -K (FVC) .V -KV (FVC) 
so slope on flow volume curve = df = -K 
dv 
So tau is the reciprocal of the slope of the flow volume curve. 
But what is tau ? 
Let us think of tau in a way which is easier to grapple with conceptually 
Recall... 
187 
tau = FVC x 0.5 =2 (t75 - t25) x 0_5 
MMEF In 3 1n3 
ie. 
tau is proportional to the time taken to expire the middle 50% of the FVC 
Question: 
Is this volume independent? 
Well if we allow Skloot's implicit assumption that the volume time curve conforms 
perfectly to a single negative exponential, then yes 
But from the above we see the implication of this is that the slope on the Flow - 








& recall as tau =1/K, 
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So we see that if subjects start their expiration at a higher lung volume then the mean 
slope on the expiratory curve (K) of the F-V loop increases. As K increases, tau 
decreases. tau being the index of bronchoconstriction then using this index, subjects 
starting their expiration at a higher lung volume will appear to have less 
bronchconstriction. 
I. e. this index is not volume independent 
For a given degree of bronchocnstriction, the higher the volume at which the partial 
expiration begins, the lower the value of tau 
Worked Example 
In the following example the numbers and calculations are taken from actual (typical) 
asthmatic and healthy subjects in the study in chapter 5, the figures are for illustrative 
purposes only. 
Fig. 1 shows the partial expiratory flow on volume-time axes at the end point of 
challenge (after 50mcg MCh) in the asthmatic subject. FET25a5, from which r is 
calculated, is 1.23 seconds. 
The curviliniarity of the volume-time curve is determined by the degree of 
bronchoconstriction. FET25.75 (and ti) is an index of this curviliniarity. Skloot argues 
that the index is independent of the volume at which the expiration is begun (EILV). 
In fact such independence is a mathematical property of a single exponential. In 
healthy subjects, to a good approximation, the volume time curve does conform to a 
single exponential, however this is not so in asthmatics. To demonstrate this, In fig. 2 
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we have re-calculated FET25a5 ( from the same curve) as if EILV had remained at its 
baseline value. The position of the `baseline EILV' is calculated using the mean 
change in EILV in the asthmatic group (15% of baseline FVC) and the assumption of 
constant TLC throughout challenge. This re-calculated FET25-75 is 1.88 seconds. 
In this subject baseline FET25a5 was 0.68 seconds. The change in FET25a5 (from 
baseline to end of challenge) recorded was therefore (1.23 minus 0.68) 0.55 seconds 
or 81%. When we re-calculate FET25_75 as if EILV had remained at its baseline value 
we find the change in FET25_75 is (1.88 minus 0.68) 1.20 seconds or 176%. Thus the 
rise in EILV that occurred during challenge had caused the measured rise in FET25a5 
(and ti) to be only 46% of that which would have been recorded had EILV remained at 
the baseline level. Ie the rise in EILV has masked the true degree of 
bronchoconstriction in the asthmatic subject. 
In the healthy control group the rise in EILV is less important for two reasons: 
(i. ) The, within challenge, rise in EILV is less than in the asthmatic group (2.5% 
vs 15%) 
(ii. ) Due to the shape of the volume-time curve the rise in EILV has less effect on 
FET2sas" 
In a typical healthy subject we found the mean 2.5% rise in EILV represented a 
change of 0.16 litres, this had no measurable effect on the FET25a5" 
In conclusion, the rise in EILV during challenge would appear to be masking a 
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